<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2105233678
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KETOVA 400 mg Film Coated Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IMATINIB MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3231.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What it does:</strong></p><ul><li>KETOVA helps slow down or stop the growth of cancer cells in your body.</li><li>KETOVA is used to treat several SOLID TUMOR or BLOOD CANCER indications. They are described in more detail below. Ask your doctor if you are not sure why KETOVA has been prescribed for you. KETOVA can be used in children for one indication.</li></ul><p>&nbsp;</p><p><strong>What it is taken for:</strong></p><ul><li>Solid tumors in adults</li><li>Blood cancers</li><li>Adults and children two years old and older with a new diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia (Ph-positive CML). The cancer is in an early phase. It is called chronic phase.</li><li>cancer of white blood cells</li><li>certain abnormal cells (called myeloid cells) are growing out of control</li></ul><p>&nbsp;</p><p><u>Blood Cancers</u><br /><em>Adults</em><br /><strong>Philadelphia chromosome-positive chronic myeloid leukemia (Ph-positive CML)<br />cancer of white blood cells</strong></p><ul><li>certain abnormal cells (called myeloid cells) are growing out of control</li><li>in chronic phase after failure of other treatment, it is called interferon</li><li>or in accelerated phase, or blast crisis. The blood cancer grows faster in these phases than in chronic phase</li></ul><p>&nbsp;</p><p><strong>Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL)</strong></p><ul><li>cancer of white blood cells</li><li>certain abnormal cells (called lymphoblasts) are growing out of control</li><li>first treatment in newly diagnosed Ph-positive ALL</li><li>or when cancer has come back after treatment</li><li>or when cancer was not successfully treated with other treatment</li></ul><p>&nbsp;</p><p><strong>Myelodysplastic/myeloproliferative diseases (MDS/MPD)</strong></p><ul><li>a group of blood diseases</li><li>too many abnormal blood cells are made</li><li>KETOVA is used in a certain sub-type of these diseases</li></ul><p>&nbsp;</p><p><strong>Aggressive systemic mastocytosis (ASM), and systemic mastocytosis with an associated clonal haematological non-mast-cell disorder (SM-AHNMD)</strong></p><ul><li>cancer of white blood cells</li><li>certain abnormal cells (called mast cells) are growing out of control</li><li>KETOVA is used in certain sub-types of these diseases.</li></ul><p>&nbsp;</p><p><strong>Advanced hypereosinophilic syndrome (HES), and chronic eosinophilic leukemia (CEL)</strong></p><ul><li>blood diseases</li><li>certain abnormal blood cells (called eosinophils) are growing out of control</li><li>KETOVA is used in a certain sub-type of these diseases</li></ul><p>&nbsp;</p><p><u>Solid Tumors</u><br /><em>Adults</em><br /><strong>Dermatofibrosarcoma protuberans (DFSP)</strong></p><ul><li>a cancer of the tissue beneath the skin</li><li>some abnormal cells are growing out of control</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Serious Warnings and Precautions</strong></p><p><br />Take KETOVA only under the care of a doctor who knows how to use anti-cancer drugs. They should be trained in how to treat solid tumors or blood cancers.</p><p>KETOVA can cause severe side effects,</p><ul><li>Heart disease or problems where your heart is unable to pump enough blood to meet the body&rsquo;s needs. These include:</li><li>Left ventricular dysfunction</li><li>Congestive heart failure</li><li>Cardiogenic shock</li><li>Water retention: a build-up of water in your body</li><li>Side effects caused by water retention. These include:</li><li>Pleural effusion</li><li>Pulmonary edema</li><li>Pericardial effusion</li><li>Ascites</li><li>Rhabdomyolysis: a rapid breakdown of muscle. It may lead to sudden kidney failure.</li><li>Severe bleeding</li><li>Liver disorder, jaundice, toxicity or failure. In some patients, liver failure has led to death.</li><li>Gastrointestinal perforation: a hole in the wall of your stomach, small or large bowel. In some patients, it has led to death.<br />&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>Do not use KETOVA if:</strong><br />You are allergic to imatinib or any of the non-medicinal ingredients found in KETOVA.<br /><strong>To help avoid side effects and ensure proper use, talk to your healthcare professional before you take KETOVA. Talk about any health conditions or problems you may have, or have ever had, including:</strong></p><ul><li>heart, liver, kidney, stomach or bowel problems</li><li>bleeding problems</li><li>bleeding from your stomach, small bowel, or large bowel</li><li>had your thyroid removed and take a thyroid hormone such as levothyroxine</li><li>if you are pregnant or are planning to get pregnant. KETOVA can harm your unborn baby. Your healthcare professional might want you to take a pregnancy test</li><li>before you take KETOVA. You should use highly effective birth control if you might get pregnant while taking KETOVA. If you become pregnant while taking KETOVA, or think you might be, tell your healthcare professional right away</li><li>Tumor Lysis Syndrome (TLS) is a serious side effect. It usually occurs after treatment of a large or fast-growing cancer. As tumor cells die certain chemicals are released into the blood. This may cause damage to organs. Before they start KETOVA, some people are at increased risk of Tumor Lysis Syndrome (TLS). If this is true for you, the doctor might give you treatments that may decrease the risk of TLS</li><li>if you are a man and are trying to have a child. Your healthcare professional may advise you not to start treatment with KETOVA while you are trying to have a child. Your healthcare professional may advise you to stop taking KETOVA before you try to have a child;</li><li>if you have ever had or might now have a hepatitis B virus infection (a viral infection of the liver). This is because during treatment with KETOVA, hepatitis B may become active again, which can be fatal in some cases. Your doctor will check for signs of this infection before and during treatment with KETOVA.</li></ul><p>&nbsp;</p><p><strong>Other warnings you should know about:</strong><br />The following list contains some of the drugs that may interact with KETOVA. Tell your healthcare professional about ALL the medicines you take including any drugs, vitamins, minerals, natural supplements or alternative medicines.</p><p>&nbsp;</p><p><strong>The following may interact with KETOVA:</strong></p><ul><li>some medicines used to treat fungal infections, like ketoconazole, itraconazole</li><li>some medicines used to treat bacterial infections, like erythromycin, or clarithromycin</li><li>some medicines used to treat epilepsy, like carbamazepine, oxcarbazepine, phenobarbital, phenytoin, fosphenytoin, or primidone</li><li>some medicines used to treat high cholesterol like simvastatin</li><li>some medicines used to treat mental health disorders like pimozide</li><li>some medicines used to treat high blood pressure or heart disorders. This includes metoprolol or a group of medicines called calcium channel blockers</li><li>rifampicin a medicine used to treat tuberculosis (TB)</li><li>St. John&rsquo;s Wort (Hypericum perforatum), a herbal product used to treat depression and other conditions</li><li>dexamethasone, a medicine to treat inflammation</li><li>cyclosporine, a medicine that keeps the immune system from rejecting a new organ after a transplant</li><li>acetaminophen, a medicine used to reduce pain or fever &mdash; acetaminophen is also included in many cold and flu remedies, so check the label</li><li>warfarin, a medicine used to treat or prevent blood clots</li><li>levothyroxine, if you had your thyroid removed</li><li>Do NOT drink grapefruit juice at any time while you are on KETOVA</li></ul><p>&nbsp;<br /><strong>Pregnancy and breast-feeding</strong><br />If you are breast-feeding, You must stop breast-feeding before taking KETOVA. It can get into breast milk and harm your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><br />Driving and using machines: Before doing tasks which require special attention, wait until you are feeling well again. Blurred vision and being dizzy or drowsy can occur.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Take KETOVA only as prescribed for you by your doctor.</p><p>If your dose is 800 mg a day, use only the 400 mg tablets to make up your dose. This will reduce how much iron you get.</p><p>Take KETOVA by mouth, with food and a large glass of water. You can take KETOVA in one of these two ways:</p><p><u>Swallowing KETOVA:</u><br />Swallow KETOVA whole with a large glass of water.<br />If the 400 mg tablet is too large to swallow whole:<br />Break it in two pieces<br />Swallow each piece with water, one after the other</p><p><u>If you cannot swallow a 400 mg tablet broken in two or a 100 mg tablet: Place the tablet in a glass with water or apple juice:</u><br />100 mg tablet: use 50 mL or one-quarter cup<br />400 mg tablet: use 200 mL or a little less than 1 cup<br />Stir with a spoon to completely dissolve the tablet<br />Drink the whole drink right away<br />Rinse the glass with a little more water or juice and drink that too<br />No trace of the dissolved tablet should be left behind in the glass</p><p>&nbsp;</p><p><strong>Usual dose:</strong><br />Your dose depends on if you are an adult or a child, and on your medical condition. Your healthcare professional will regularly monitor your condition. Your dose may change depending on how well KETOVA is working.</p><table border="1" cellspacing="0" cellpadding="0" align="center"><tbody><tr><td><p><strong>Age Group</strong></p><p>&nbsp;</p></td><td><p><strong>Indication</strong></p></td><td><p><strong>Daily Dose</strong></p></td><td><p><strong>Instructions for Use</strong></p></td></tr><tr><td rowspan="3"><p><strong>Adults</strong></p></td><td><p><strong>Philadelphia chromosome-positive chronic myeloid leukemia (Ph- positive CML)</strong></p></td><td><p><strong>Usual dose: </strong>400 mg or 600 mg</p><p>Depending on how you respond to treatment you may get a higher or lower dose.</p><p>&nbsp;</p><p>If your dose is 800 mg per day</p></td><td><p>Take once a day</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Take twice a day. A 400 mg tablet in the morning and another 400 mg tablet in the evening.</p></td></tr><tr><td><p><strong>Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL</strong>)</p></td><td><p>600 mg</p></td><td><p>Take once a day</p></td></tr><tr><td><p><strong>Myelodysplastic/myeloprolifera-tive diseases (MDS/MPD)</strong></p></td><td><p>400 mg</p></td><td><p>Take once a day</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Age Group</strong></p></td><td><p><strong>Indication</strong></p></td><td><p><strong>Daily Dose</strong></p></td><td><p><strong>Instructions for Use</strong></p></td></tr><tr><td rowspan="3" colspan="1"><p><strong>Adults</strong></p><p>&nbsp;</p></td><td><p><strong>Aggressive systemic mastocytosis (ASM) and systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM- AHNMD)</strong></p><ul><li>without a certain mutation (called D816V c-Kit).</li><li>status of a certain mutation (called D816V c-Kit) is unknown. And, response to other therapies has not been good enough.</li><li>associated with an abnormal increase in certain blood cells (called eosinophils).</li></ul></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>400 mg</p><p>&nbsp;</p><p>400 mg</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Starting dose: </strong>100 mg. May be increased to 400 mg depending on how you respond to treatment.</p></td><td><p>Take once a day</p></td></tr><tr><td><p><strong>Hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL)</strong></p></td><td><p><strong>Starting dose: </strong>100 mg. May be increased to 400 mg depending on how you respond to treatment</p></td><td><p>Take once a day</p></td></tr><tr><td><p><strong>Dermatofibrosarcoma -protuberans (DFSP)</strong></p></td><td><p>800 mg</p></td><td><p>Take twice a day. A 400 mg tablet in the morning and another 400 mg tablet in the evening</p></td></tr><tr><td><p><strong>Children:</strong></p><p><strong>2 years of age and older</strong></p></td><td><p><strong>Philadelphia chromosome-positive chronic myeloid leukemia (Ph- positive CML)</strong></p></td><td><p>Depending on the child&rsquo;s weight and height, 100 mg to 600 mg</p></td><td><p>As prescribed by the doctor:</p><p>Take once a day OR split into two doses, one in the morning and one in the evening</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>If you take KETOVA more than you should:</strong><br />If you think you have taken too much KETOVA, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.</p><p>&nbsp;</p><p><strong>If you forget to take KETOVA:</strong><br />If you or your child:<br />missed a dose OR threw up after taking the last dose. Do NOT take another dose or double dose. Instead, wait until it is time for your next dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>These are not all the possible side affects you may feel when taking KETOVA. If you experience any side effects not listed here, contact your healthcare professional. Please also read the box called &ldquo;Serious Warnings and Precautions&rdquo;.</p><p><strong>Side effects may include:</strong></p><ul><li>weight loss, no appetite, change in taste, dry mouth, sores in mouth</li><li>heartburn, indigestion</li><li>constipation, gas, feel bloated</li><li>headache, dizziness</li><li>difficulty sleeping, drowsiness</li><li>weakness, feeling tired</li><li>nosebleeds</li><li>skin dry, itchy or less sensitive to touch</li><li>skin more sensitive to sun</li><li>night sweats, red in the face or other areas of the skin</li><li>unusual hair loss or thinning</li><li>muscle tension, cramps, pain</li><li>bone pain</li><li>joint pain and swelling</li><li>tingling, pain, or numbness in hands, feet, legs</li><li>cough<br />&nbsp;</li></ul><p>If any of these affects you severely, tell your healthcare professional.<br />KETOVA can cause abnormal blood test results. You may have blood thyroid hormone levels that are not normal. This occurs when your thyroid has been removed and you are on a drug such as levothyroxine.</p><p>Children who take KETOVA may have the following side effects more often than adults:</p><ul><li>Low blood levels of calcium, sugar, phosphates, albumin protein and sodium</li><li>High blood levels of sugar</li></ul><p>Your doctor will decide when to perform tests and will interpret the results.</p><p>While you are taking KETOVA, you will be weighed regularly.<br />Children and teenagers may grow more slowly when taking KETOVA. The healthcare professional will measure their growth at regular visits.</p><p>Your doctor may do blood and/or urine tests to check how well your kidneys are working. This will be done before you start taking KETOVA and during your treatment if you have had hepatitis B (a viral infection of the liver) in the past.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p><strong>Serious side effects and what to do about them</strong></p></td></tr><tr><td rowspan="2"><p>&nbsp;</p><p><strong>Symptom / effect</strong></p></td><td colspan="2"><p><strong>Talk to your healthcare</strong></p><p><strong>professional</strong></p></td><td rowspan="2"><p><strong>Stop taking drug and get</strong></p><p><strong>immediate medical help</strong></p></td></tr><tr><td><p>&nbsp;</p><p><strong>Only if severe</strong></p></td><td><p>&nbsp;</p><p><strong>In all cases</strong></p></td></tr><tr><td><p><strong>VERY COMMON</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Water retention: </strong>rapid weight gain, swelling of your hands, ankles, feet, face, or eyelids, or your whole body.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Decreased Platelets:</strong>&nbsp;bruising, bleeding, fatigue and weakness.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Decreased White Blood Cells: </strong>infections, fatigue,</p><p>fever, aches, pains, and flu- like symptoms.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Anemia </strong>(Decreased red blood cells): fatigue, loss of energy, weakness, shortness of breath.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Musculoskeletal pain after discontinuing treatment with KETOVA:</strong>&nbsp;muscle pain, limb pain, joint pain and bone pain.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>COMMON</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Pleural effusion </strong>(fluid around the lungs): chest pain. Difficult or painful breathing, cough.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Pulmonary edema </strong>(fluid in the air spaces of the lungs): difficult breathing that is worse when you lie down. Cough up blood or blood- tinged froth.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Pericardial effusion </strong>(fluid around the heart): chest pain that feels better when you sit up rather than lie down. Feel light-headed or pass out. Irregular, fast, or forceful heartbeat. Difficult or painful breathing, cough.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Ascites </strong>(fluid in the abdomen): feeling of fullness, abdominal pain, shortness of breath.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Bleeding or swelling in the brain: </strong>severe headache. Weak or cannot move arms, legs or face. Difficulty talking, fainting or passing out. Dizziness, blurred vision, seizure (fit).</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Pneumonia </strong>(infection in the lungs): shortness of breath. Difficult and painful breathing, cough, wheezing, or fever.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Shortness of Breath</strong></p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Chest Pain</strong></p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Inflammatory bowel disease: </strong>nausea, vomiting, diarrhea, abdominal pain, fever.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Liver disorder, jaundice, toxicity, or failure: </strong>yellow skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p>Vomiting</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pain in the abdomen</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fever</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Less urine, urinate less often.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Eye Infection</strong>&nbsp;(conjunctivitis)<strong>: </strong>itchy, red eyes with discharge, and swelling.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Increased tears in the eyes, dry eyes.</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Swelling around the eyes or in the eyelids.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>UNCOMMON</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Bleeding in the stomach or bowels: </strong>severe abdominal pain, vomit blood, black or bloody bowel movement, swelling of the abdomen. Feel dizzy or weak, loss of consciousness. Shortness of breath.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Gastrointestinal perforation (</strong>a hole in the wall of your stomach or bowels): severe abdominal pain, nausea, vomiting, chills or fever.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Decreased or increased levels of potassium in the blood: </strong>irregular heartbeats, muscle weakness and generally feeling unwell.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Interstitial lung disease </strong>(diseases that inflame or scar lung tissue): shortness of breath, tiredness, dry cough.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Acute respiratory failure: </strong>sudden worsening of shortness of breath, bluish color on skin, lips, and fingernails, irregular heartbeats, feel sleepy, loss of consciousness.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Low Blood Pressure: </strong>dizziness, fainting, light- headedness.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fainting or passing out</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Difficulty hearing</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Blood in urine</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Left ventricular dysfunction, Congestive heart failure </strong>(a weakness of the heart)<strong>:</strong>&nbsp;tiredness, swollen ankles, shortness of breath especially when lying down.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Heart attack (</strong>blood flow stops to part of the heart): sudden chest pain or pressure or discomfort, feeling faint, shortness of breath, possibly irregular heartbeat.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Cardiogenic shock </strong>(heart is not able unable to pump enough blood to the organs of the body): breathe fast, fast heartbeat, loss of consciousness, sweating, pale skin, cold hands or feet.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Angina (</strong>not enough oxygen to the heart muscle): chest pain or pressure, usually coming during exercise or physical stress and relieved by rest.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Raynaud&rsquo;s syndrome: </strong>fingers and toes feel numb and cold in response to cold temperatures or stress.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Cellulitis </strong>(infection under the skin): red, hot, painful and swollen area.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Palmar-plantar erythrodysaesthesia syndrome: </strong>red or swollen&nbsp;palms of the hands and soles of the feet. You might feel a tingling or burning pain as well.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Tumor lysis syndrome </strong>nausea, shortness of breath, irregular heartbeat, cloudy urine, tiredness, or pain in joints.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>RARE</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Eye Problems:</strong>&nbsp;blood in eye, trouble seeing, blurred vision.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Pulmonary fibrosis </strong>(scarring of the lung tissues): shortness of breath, tiredness, dry cough.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Seizure</strong></p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Erythema multiforme </strong>(an allergic skin reaction): raised red or purple skin patches, possibly with blister or crust in the center. Possibly swollen lips. Mild itching or burning.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Stevens Johnson syndrome, Toxic epidermal necrolysis&nbsp;</strong>(severe skin reaction): rash, red skin, red or purple skin patches possibly with blister or crust in the center, pus-filled rash, peeling skin, blisters on the lips, eyes, skin or in the mouth, itching, burning, flu-like feeling, fever.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Breakdown of red blood cells: </strong>pale skin, feeling tired or out of breath, dark urine.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>UNKNOWN FREQUENCY</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Allergic reactions: </strong>itch, rash, hives, swelling of the lips, tongue or throat, difficulty swallowing or breathing.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Drug reaction with eosinophilia and systemic symptoms (DRESS) </strong>(severe reaction to a medicine. Your skin and one or more of the organs in your body are involved. You may only have some of the side effects that are listed here): fever, severe rash, swollen lymph glands, flu-like feeling, yellow skin or eyes, shortness of breath, dry cough, chest pain or discomfort, feel thirsty, urinate less often, less urine.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p><strong>Rhabdomyolysis (</strong>a rapid breakdown of muscle): unexplained muscle pain, tenderness or weakness. Dark brown urine.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Blood clot in blood vessel:</strong>&nbsp;swelling, redness and pain in one part of the body.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gynecological disorder </strong>(problem in woman&rsquo;s reproductive system)<strong>: </strong>pain in lower abdomen or unexpected blood from the vagina or both.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Avascular necrosis / Hip osteonecrosis </strong>(break down and collapse of bone tissue.): pain and difficulty while walking.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Chronic Kidney Impairment</strong>&nbsp;(reduced kidney function).</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Hepatitis B virus reactivation </strong>(an active viral infection of the liver): Fever, skin rash, joint pain and inflammation as well as tiredness, loss of appetite, nausea, jaundice (yellowing of the skin or whites of eyes), pain in the upper right abdomen, pale stools and dark urine.</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>These are not all the possible side affects you may feel when taking KETOVA. If you are bothered by a side effect not listed here, talk to your healthcare professional. If you have a symptom or side effect that begins to affect your daily activities, talk to your healthcare professional.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store below 30&deg;C in the original package.</li><li>Do not use KETOVA after the expiry date shown on the box.</li><li>Do not use any KETOVA pack that is damaged or shows signs of tampering.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What the medicinal ingredient is:</strong></p><ul><li>The active substance is Imatinib Mesylate.</li><li>The other ingredients are crospovidone, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methyl cellulose 2910, hydroxypropyl cellulose, polyethylene glycol, red ferric oxide and yellow ferric oxide.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Brownish orange, slightly biconvex round film-coated tablet, engraved “IMA” over score “100” on one side and “APO” on the other side.
Brownish orange, capsule shaped, biconvex film-coated tablet. Engraved “IMA” score “400” on one side, “APO” on the other side.

Available in bottles of 30 and 500.
Available in blister packs of 30 tablets (3 blisters of 10 tablets each), and in blister packs of 100 tablets (10 blisters of 10 tablets each.
Not all pack sizes may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.<br />Telephone: 416-401-7500<br />Fax: 416-401-3875<br />E-mail: support@apotex.com</p><p><strong>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</strong><br />Apotex Inc. Saudi Arabia<br />Tahliya Street, Jeddah<br />00966122631960<br />aaldawoo@apotex.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised 12/2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو كيتوفا؟</strong><br />يساعد كيتوفا على إبطاء أو إيقاف تكاثر الخلايا السَّرَطانيَّة في الجسم.<br />يُستخدم كيتوفا لعلاج العديد من عوارض الأورام الصلبة أو سرطان الدم. وفيما يلي وصف مفصل عن الدواء. استشر طبيبك إذا لم تكن متأكدًا من سبب وصف كيتوفا لك. يمكن أن يُستخدم كيتوفا للأطفال لعلاج حالة واحدة من الأعراض.</p><p>&nbsp;</p><p><strong>فيم يُستخدم؟</strong></p><ul><li>الأورام الصلبة لدى البالغين</li><li>&nbsp;المصابين بسرطانات الدم</li><li>للبالغين والأطفال من عمر عامين وفيما فوق الذين تم تشخيصهم حديثًا بالإصابة بـابيضاض الدم النَّقوي المزمن إيجابي صبغي فيلادلفيا(Ph-positive CML)، والتي يكون فيها السرطان في مرحلته المبكرة، والتي تسمى المرحلة المزمنة.</li><li>سرطان خلايا الدم البيضاء.</li><li>خروج بعض خلايا محددة غير طبيعية (تسمى الخلايا النَّقوية) عن السيطرة.</li></ul><p>&nbsp;</p><p><u><strong>سرطانات الدم</strong></u><br /><u>البالغون</u><br /><strong>ابيضاض الدم النَّقوي المزمن- إيجابي صبغي فيلادلفيا (Ph-positive CML):</strong></p><ul><li>سرطان خلايا الدم البيضاء.</li><li>خروج بعض خلايا محددة غير طبيعية (تسمى الخلايا النَّقوية) عن السيطرة.</li><li>في المرحلة المزمنة بعد فشل نوع علاج آخر، يسمى بالإنترفيرون.</li><li>أو في المرحلة المتسارعة أو النوبة الأرومية. حيث يتسارع نمو سرطان الدم في هذه المراحل عنه في المرحلة المزمنة.</li></ul><p>&nbsp;</p><p><strong>ابيضاض الدم اللمفاوي الحاد إيجابي صبغي فيلادلفيا (Ph-positive ALL):</strong></p><ul><li>سرطان خلايا الدم البيضاء.</li><li>خروج بعض خلايا محددة غير طبيعية (تسمى الخلايا اللمفاوية) عن السيطرة.</li><li>العلاج الأول في ابيضاض الدم اللمفاوي الحاد إيجابي صبغي فيلادلفيا، المشخص حديثًا.</li><li>أو عند معاودة السرطان بعد العلاج.</li><li>أو في حالة عدم نجاح علاج السرطان باستخدام علاج آخر.</li></ul><p>&nbsp;</p><p><strong>أمراض التكاثر النخاعي أو خلل التنسج النخاعي (MDS/MPD):</strong></p><ul><li>مجموعة من أمراض الدم.</li><li>إنتاج العديد من خلايا الدم غير الطبيعية.</li><li>يستخدم كيتوفا في نوع فرعي محدد من هذه الأمراض.</li></ul><p>&nbsp;</p><p><strong>كثرة الخلايا البدينة الجهازي الهجومي (ASM) وكثرة الخلايا البدنية الجهازي مع اضطراب الخلايا غير البدنية النسيلية في الدم المرتبطة بها (SM-AHNMD):</strong></p><ul><li>سرطان خلايا الدم البيضاء.</li><li>خروج بعض خلايا محددة غير طبيعية (تسمى الخلايا البدنية) عن السيطرة.</li><li>يستخدم كيتوفا في نوع فرعي محدد من هذه الأمراض.</li></ul><p>&nbsp;</p><p><strong>متلازمة فرط اليوزينيات المتقدمة (HES) وابيضاض اليوزبنيات المزمن (CEL):</strong></p><ul><li>أمراض الدم.</li><li>خروج بعض خلايا محددة غير طبيعية (تسمى الخلايا اليوزينية) عن السيطرة.</li><li>يستخدم كيتوفا في نوع فرعي محدد من هذه الأمراض.</li></ul><p>&nbsp;</p><p><u><strong>الأورام الصلبة</strong><br />البالغون</u><br /><strong>ساركوما ليفية جلدية حدبية (DFSP):</strong></p><ul><li>سرطان الأنسجة تحت الجلد.</li><li>خروج بعض الخلايا غير الطبيعية عن السيطرة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>تحذيرات هامة واحتياطات</strong></p><p>لا يستخدم كيتوفا إلا تحت عناية طبيب يعرف كيفية استخدام أدوية علاج السرطان. إذ يجب أن يكون مدربًا على كيفية علاج الأورام الصلبة أو أورام الدم.<br />من الممكن أن يتسبب كيتوفا في حدوث آثار جانبية شديدة.</p><p><strong>أمراض القلب أو مشكلات</strong> يكون فيها القلب غير قادر على ضخ ما يكفي من الدم لتلبية احتياجات الجسم، وتشمل:</p><ul><li dir="rtl"><strong>اختلال وظيفة البطين الأيسر.</strong></li><li dir="rtl"><strong>فشل القلب الاحتقاني.</strong></li><li dir="rtl"><strong>صدمة قلبية.</strong></li><li dir="rtl"><strong>احتباس الماء:</strong> تراكم الماء في جسمك.</li><li dir="rtl"><strong>الآثار الجانبية الناتجة عن احتباس الماء</strong>، والتي تشمل:</li><li dir="rtl">الانصباب الجنبي.</li><li dir="rtl">ذمة الرئة.</li><li dir="rtl">انصباب التأمور.</li><li dir="rtl">الاستسقاء.</li><li dir="rtl"><strong>انحلال الربيدات:</strong> انحلال سريع للعضلات، قد يؤدي إلى فشل كلوي مفاجئ.</li><li dir="rtl"><strong>نزيف شديد.</strong></li><li dir="rtl"><strong>مرض الكبد، أو اليرقان، أو تسمم الكبد أو الفشل الكبدي.</strong> لدى بعض المرضى، أدى الفشل الكبدي إلى الوفاة.</li><li dir="rtl"><strong>الثقب المعوي المعدي: </strong>ثقب في جدار المعدة أو الأمعاء الدقيقة أو الغليظة. لدى بعض المرضى، أدى هذا إلى الوفاة.&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>لا تستخدم كيتوفا، إذا:</strong><br />كنت تعاني من حساسية من إيماتينيب أو أي مكونات غير طبية موجودة بكيتوفا</p><p><strong>للمساعدة في تجنب الآثار الجانبية، والتأكد من الاستعمال الملائم، تحدث مع أخصائي الرعاية الصحية لديك قبل تناول كيتوفا، عن أي ظروف أو مشكلات صحية قد تشهدها أو شهدتها بالفعل، والتي تشمل:</strong></p><ul><li>مشكلات القلب أو الكبد أو الكلى أو المعدة أو الأمعاء.</li><li>مشكلات النزيف.</li><li>نزيف المعدة أو الأمعاء الدقيقة أو الأمعاء الغليظة.&nbsp;</li><li>استئصال الغدة الدرقية وتناول هرمون للغدة الدرقية مثل ليفوثيروكسين.</li><li>إذا كنتِ حاملاً أو تخططين للحمل، فقد يضر كيتوفا بالجنين. قد يرغب أخصائي الرعاية الصحية في إخضاعك لاختبار الحمل قبل تناول كيتوفا. ينبغي عليك استعمال وسيلة منع حمل عالية الفعالية، في حال احتمال حدوث حمل أثناء تناول كيتوفا. في حال حدوث حمل أو الاعتقاد بحدوث حمل أثناء تناول كيتوفا، أخبري أخصائي الرعاية الصحية على الفور.</li><li>متلازمة تحلل الورم (TLS)، هو عرض جانبي خطير، يحدث عادة بعد علاج السرطان المنتشر أو سريع النمو. فنتيجة لموت الخلايا السَّرَطانيَّة، تُطلق مواد كيميائية محددة بالدم، مما قد يؤدي إلى تلف الأعضاء. ويعتبر بعض الأشخاص في خطر متزايد للإصابة بمتلازمة تحلل الورم، قبل البدء في تناول كيتوفا. لذلك إذا كان هذا ينطبق عليك، فقد يصف لك الطبيب أنواع علاج قد تقلل من خطر الإصابة بمتلازمة تحلل الورم.</li><li>إذا كنت رجلاً وتسعى لإنجاب طفل، فقد ينصحك أخصائي الرعاية الصحية بعدم البدء في تناول علاج كيتوفا، بينما تحاول إنجاب طفل. بل ربما قد ينصحك أخصائي الرعاية الصحية بالتوقف عن استخدام كيتوفا قبل محاولة إنجاب طفل.</li><li>إذا سبقت لك الإصابة بعدوى التهاب الكبد الفيروسي ب، أو من المحتمل إصابتك به في الفترة الحالية (عدوى فيروسية في الكبد)، فسيتحقق طبيبك من علامات إصابتك بالعدوى قبل العلاج بكيتوفا وأثناء العلاج به؛ نظرًا لاحتمالية نشاط التهاب الكبد الفيروسي ب من جديد، أثناء الخضوع لعلاج كيتوفا، مما قد يكون مميتًا في بعض الحالات.</li></ul><p>&nbsp;</p><p><strong>تحذيرات أخرى ينبغي عليك معرفتها:</strong><br />تتضمن القائمة التالية بعض أنواع العقاقير التي قد تتفاعل مع كيتوفا. أخبر أخصائي الرعاية الصحية لديك عن جميع الأدوية التي تتناولها بما في ذلك العقاقير أو الفيتامينات أو المعادن أو المكملات الطبيعية أو الأدوية البديلة.</p><p>&nbsp;</p><p><strong>قد تتفاعل الأدوية التالية مع كيتوفا:</strong></p><ul><li>بعض الأدوية التي تُستخدم لعلاج العدوى الفطرية مثل الكيتوكونازول، وإيتراكونازول.</li><li>بعض الدوية التي تُستخدم لعلاج العدوى البكتيرية مثل إريثرومايسين أو الكلاريثرومايسين.</li><li>بعض الأدوية التي تُستخدم لعلاج الصرع مثل كاربامازيبين، أو أوكسكاربازيبين، أو فينوباربيتال، أو فينيتوين، أو فوسفنتوين، أو بريميدون.</li><li>بعض الأدوية التي تستخدم لعلاج ارتفاع الكوليسترول مثل سيمفاستاتين.</li><li>بعض الأدوية التي تستخدم لعلاج اضطرابات الصحة العقلية مثل بيموزيد.</li><li>بعض الأدوية التي تستخدم لعلاج ارتفاع ضغط الدم أو اضطرابات القلب. والتي تشمل ميتوبرولول أو مجموعة من الأدوية التي يطلق عليها اسم حاصرات قنوات الكالسيوم.</li><li>ريفامبيسين، دواء يستخدم لعلاج السل.</li><li>نبتة سانت جون (هيبيريكوم بيرفوراتوم) وهو منتج عشبي يستخدم لعلاج الاكتئاب وحالات أخرى.</li><li>ديكساميثازون، دواء لعلاج الالتهاب.</li><li>سايكلوسبورين، دواء يقي جهاز المناعة من رفض عضو جديد بعد عملية الزرع.</li><li>اسيتامينوفين، دواء يستخدم للحد من الألم أو الحمى &ndash; يدخل الاسيتامينوفين أيضًا في العديد من علاجات البرد والأنفلونزا؛ لذلك تحقق من التسمية.</li><li>الوارفارين، دواء يستخدم لعلاج أو منع جلطات الدم.&nbsp;</li><li>ليفوثيروكسين، في حالة استئصال الغدة الدرقية.</li><li>لا تتناول عصير الجريب فروت في أي وقت أثناء تناول كيتوفا.</li></ul><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية&nbsp;</strong><br />إذا كنتِ تقومين بالرضاعة الطبيعية، يجب عليكِ الامتناع عن الرضاعة الطبيعية أثناء تناولكِ لكيتوفا؛ لأنه ينتقل إلى حليب الأم ويمكن أن يؤثر على الطفل.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong><br />القيادة واستخدام الآلات: قبل أداء أي مهام تتطلب انتباهًا خاصًا، انتظر حتى تشعر أنك على ما يرام مرة أخرى. فقد تشعر بعدم وضوح الرؤية والدوار أو النعاس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائمًا كما أخبرك طبيبك تمامًا.&nbsp;<br />إذا كانت الجرعة التي تتناولها 800 ملجم يوميًا، فاستخدم الأقراص المحتوية على 400 ملجم لتعويض جرعتك. إن هذا من شأنه خفض معدل الحديد الذي تحصل عليه.<br />تناول كيتوفا عن طريق الفم، مع الطعام أو مع كوب كبير من الماء. يمكنك تناول كيتوفا باتباع إحدى الطريقتين التاليتين:</p><p><u>ابتلاع كيتوفا:</u></p><ul><li>ابتلع القرص بالكامل مع كوب كبير من الماء.</li><li>إذا كان القرص 400 ملجم كبيرًا جدًا ليتم ابتلاعه بالكامل: اكسر القرص إلى جزءين، وابتلع كل جزء على حدة بالماء، الواحد تلو الآخر.</li></ul><p>&nbsp;</p><p><u><strong>إذا لم تتمكن من ابتلاع</strong> القرص 400 ملجم مكسورًا إلى جزئين أو القرص 100 ملجم: فضع القرص في كوب من الماء أو عصير التفاح.</u></p><ul><li>للقرص 100 ملجم: استخدم 50 ملل أو ربع كوب.&nbsp;</li><li>للقرص 400 ملجم: استخدم 200 ملل أو أقل من كوب واحد بقليل.</li><li>حرك باستخدام ملعقة حتى تمام ذوبان القرص بالكامل.</li><li>تناول المشروب كله على الفور.</li><li>اشطف الكوب بالقليل من الماء أو العصير، وتناول هذه الكمية أيضًا.</li><li>ينبغي ألَّا تترك أي مقدار من القرص المذاب في الكوب.</li></ul><p>&nbsp;</p><p><strong>الجرعة المعتادة:</strong><br />تعتمد جرعتك على إذا ما كنت طفلاً أو بالغًا، وأيضًا على حالتك الطبية، حيث سيراقب أخصائي الرعاية الصحية حالتك بانتظام. قد تتغير الجرعة بناءً على مدى فعالية عمل كيتوفا.</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>المجموعة العمرية</strong></p></td><td><p dir="RTL"><strong>دواعي الاستخدام</strong></p></td><td><p dir="RTL"><strong>الجرعة اليومية</strong></p></td><td><p dir="RTL"><strong>تعليمات الاستخدام</strong></p></td></tr><tr><td rowspan="6" colspan="1"><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td><td><p dir="RTL"><strong>ابيضاض الدم النَّقوي المزمن إيجابي صبغي فيلادلفيا (</strong><strong>Ph-positive CML</strong><strong>).</strong></p></td><td><p dir="RTL">الجرعة المعتادة: 400 ملجم أو 600 ملجم.</p><p dir="RTL">قد تحتاج لجرعة أقل أو أكبر، بناءً على مدى استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت جرعتك 800 ملجم يوميًا.</p></td><td><p dir="RTL">مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مرتين يوميًا. قرص 400 ملجم صباحًا، وقرص آخر 400 ملجم مساءً.</p></td></tr><tr><td><p dir="RTL"><strong>ابيضاض الدم اللمفاوي الحاد إيجابي صبغي فيلادلفيا (</strong><strong>Ph-positive ALL</strong><strong>).</strong></p></td><td><p dir="RTL">600 ملجم.</p></td><td><p dir="RTL">مرة واحدة يوميًا.</p></td></tr><tr><td><p dir="RTL"><strong>أمراض التكاثر النخاعي أو خلل التنسج النخاعي (</strong><strong>MDS/MPD</strong><strong>).</strong></p></td><td><p dir="RTL">400 ملجم.</p></td><td><p dir="RTL">مرة واحدة يوميًا.</p></td></tr><tr><td><p dir="RTL"><strong>كثرة الخلايا البدينة الجهازي الهجومي (</strong><strong>ASM</strong><strong>) وكثرة الخلايا البدنية الجهازي مع اضطراب الخلايا غير البدنية النسيلية في الدم المرتبطة بها (</strong><strong>SM-AHNMD</strong><strong>)</strong></p><ul dir="rtl"><li>بدون طفرة محددة (تسمى D816V c-Kit)&nbsp;.</li><li>حالات طفرات محددة (تسمى D816V c-Kit) غير معروفة. لم تكن الاستجابة جيدة بما يكفي، لأنواع علاج أخرى</li><li>مرتبط بزيادة غير طبيعية في خلايا دم محددة (تسمى اليوزينية).</li></ul></td><td><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة البداية</strong>: 100 ملجم. يمكن زيادتها إلى 400 ملجم، بناءً على مدى الاستجابة للعلاج.</p></td><td><p dir="RTL">مرة واحدة يوميًا.</p></td></tr><tr><td><p dir="RTL"><strong>متلازمة فرط اليوزينيات المتقدمة (</strong><strong>HES</strong><strong>) وابيضاض اليوزبنيات المزمن (</strong><strong>CEL</strong><strong>).</strong></p></td><td><p dir="RTL"><strong>جرعة البداية</strong>: 100 ملجم. يمكن زيادتها إلى 400 ملجم، بناءً على مدى كيفية استجابتك للعلاج</p></td><td><p dir="RTL">مرة واحدة يوميًا.</p></td></tr><tr><td><p dir="RTL"><strong>ساركوما ليفية جلدية حدبية </strong><strong>(DFSP)</strong><strong>.</strong></p></td><td><p dir="RTL">800 ملجم.</p></td><td><p dir="RTL">مرتين يوميًا. قرص 400 ملجم صباحًا، وقرص آخر 400 ملجم مساءً.</p></td></tr><tr><td><p dir="RTL"><strong>الأطفال: من عمر عامين وفيما فوق.</strong></p></td><td><p dir="RTL"><strong>ابيضاض الدم النَّقوي المزمن إيجابي صبغي فيلادلفيا (</strong><strong>Ph-positive CML</strong><strong>).</strong></p></td><td><p dir="RTL">بناءً على وزن الطفل وطوله، من 100 ملجم إلى 600 ملجم.</p></td><td><p dir="RTL">وفقًا لما يصفه الطبيب:</p><p dir="RTL">مرة يوميًا أو يُجزأ على جرعتين؛ مرة صباحًا وأخرى مساءً.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>إذا تناولت جرعة كيتوفا أكثر مما ينبغي:</strong><br />إذا كنت تعتقد أنك تناولت جرعة كبيرة من كيتوفا، فاتصل فورًا بأخصائي الرعاية الصحية أو بقسم الطوارئ بالمستشفى أو بالمركز الإقليمي لمراقبة السموم، حتى وإن لم تظهر أي أعراض.</p><p>&nbsp;</p><p><strong>إذا نسيت أن تتناول كيتوفا:</strong><br />إذا حدث معك أو مع طفلك:<br />نسيان تناول جرعة أو التقيؤ بعد تناول آخر جرعة، فلا تتناول جرعة أخرى أو تضاعف الجرعة. انتظر حتى يحين موعد الجرعة التالية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>فيما يلي جميع الآثار الجانبية المحتملة التي قد تشعر بها عند تناول كيتوفا. إذا شعرت بأي أعراض جانبية ليست مدرجة في هذه النشرة، فاتصل بأخصائي الرعاية الصحية لديك. برجاء قراءة أيضًا المربع الذي يحمل اسم &laquo;تحذيرات هامة واحتياطات&raquo;.</p><p>قد تشمل الآثار الجانبية:</p><ul><li>فقدان الوزن، فقدان الشهية، تغير في الطعم، جفاف في الفم، قروح في الفم.</li><li>حرقة المعدة، وعسر هضم.</li><li>الإمساك، والغازات، والشعور بالانتفاخ.</li><li>الصداع، والدوخة.</li><li>صعوبة النوم، والنعاس.</li><li>الوهن، والشعور بالتعب.</li><li>نزيف الأنف.</li><li>جفاف الجلد، والحكة أو حساسية أقل للمس.</li><li>حساسية أكبر لأشعة الشمس.</li><li>تعرق ليلي، واحمرارًا في الوجه ومناطق أخرى بالبشرة.</li><li>تساقط الشعر أو ترققه على نحو غير معتاد.&nbsp;</li><li>توتر عضلي، تشنج العضلات، ألم العضلات.</li><li>آلام العظام.</li><li>آلام المفاصل والتورم.</li><li>الوخز أو الألم أو الخدر في اليدين والقدمين والساقين.</li><li>السعال.</li></ul><p>&nbsp;</p><p>في حال عانيت بشدة من أيٍ من هذه الأعراض، أخبر أخصائي الرعاية الصحية الخاص بك.<br />يمكن أن يتسبب كيتوفا في ظهور نتائج غير طبيعية لاختبارات الدم. كما قد تشهد مستويات غير طبيعية بهرمون الغدة الدرقية، ويحدث هذا عند استئصال الغدة الدرقية، وتناول عقاقير مثل ليفوثيروكسين.</p><p>قد يعاني الأطفال ممن يتناولون كيتوفا من أعراض جانبية أكثر من تلك التي يعاني منها البالغون والتي تشمل:</p><ul><li>انخفاض مستوى الكالسيوم والسكر والفوسفات والألبومين والصوديوم في الدم.</li><li>ارتفاع مستويات السكر في الدم.</li></ul><p>يقرر طبيبك متى تُجرَّى الاختبارات، ويُفسر النتائج.<br />ستخضع أثناء تناولك دواء كيتوفا، لقياس الوزن باستمرار.<br />قد يتباطأ نمو الأطفال والمراهقين عند تناول عقار كيتوفا. يقيس أخصائي الرعاية الصحية نموهم في زيارات منتظمة.</p><p>قد يُجري طبيبك اختبارًا للدم أو للبول أو كليهما، للتحقق من مدى كفاءة عمل الكلى لديك. وسوف تخضع لهذا الاختبار قبل البدء في تناول كيتوفا وأثناء العلاج إذا كنت مصابًا في الماضي بالتهاب الكبد الفيروسي ب (عدوى فيروسية في الكبد).</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p dir="RTL"><strong>أعراض جانبية خطيرة وكيفية التعامل معها</strong></p></td></tr><tr><td rowspan="2"><p dir="RTL"><strong>العرض/ التأثير</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى أخصائي الرعاية الصحية لديك.</strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن تناول الدواء واحصل على المساعدة الطبية فورًا.</strong></p></td></tr><tr><td><p dir="RTL"><strong>إذا كانت شديدة فقط.</strong></p></td><td><p dir="RTL"><strong>في جميع الحالات.</strong></p></td></tr><tr><td><p dir="RTL"><strong>شائعة جدًا.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>احتباس الماء</strong>: الزيادة السريعة في الوزن، تورم اليدين، أو الكاحلين أو القدمين أو الوجه أو الجفون أو الجسم بالكامل.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>نقص الصفائح الدموية: </strong>الكدمات، النزيف، التعب، الوهن.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>انخفاض عدد خلايا كرات الدم البيضاء</strong>: الالتهابات، التعب، الحمى، وجع، ألم، أعراض تشبه الأنفلونزا.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>أنيميا (انخفاض عدد خلايا الدم الحمراء): </strong>التعب، فقدان الطاقة، الوهن، ضيق التنفس<strong>.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>ألم في العضلات والعظام بعد التوقف عن تناول كيتوفا</strong>: آلام في العضلات، آلام في الأطراف، آلام في المفاصل، آلام في العظام.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>شائعة</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>الانصباب الجنبي</strong> (سوائل حول الرئة): ألم في الصدر. صعوبة أو ألم في التنفس، السعال.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>ذمة الرئة </strong>(سائل في المساحات الهوائية للرئة): صعوبة في التنفس يتزايد حدته عند الاستلقاء. السعال الدموي أو الزبد الملطخ بالدماء.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>انصباب التأمور </strong>(سائل حول القلب):<strong> </strong>ألم في الصدر يتحسن عند الجلوس منتصبًا أكثر من الاستلقاء. الشعور بخفة الرأس أو فقدان الوعي. ضربات قلب سريعة أو غير منتظمة. صعوبة أو ألم في التنفس، السعال.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>استسقاء </strong>(سائل في البطن): الشعور بالامتلاء، و آلام في البطن، وضيق في التنفس.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>نزيف أو تورم في الدماغ</strong>: صداع شديد. ضعف أو صعوبة في تحريك الذراعين أو الساقين أو الوجه. صعوبة في الكلام، أو الإغماء، أو فقدان الوعي. الدوخة، عدم وضوح الرؤية، ونوبة تشنج.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>الالتهاب الرئوي (عدوى في الرئتين): </strong>ضيق في التنفس. صعوبة وألم في التنفس، أو السعال أو صفير التنفس أو الحمى.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>ضيق التنفس.</strong></p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>ألم في الصدر.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>داء الأمعاء الالتهابي: </strong>الغثيان، القيء، الإسهال، آلام في البطن، الحمى.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>مرض الكبد، أو اليرقان، أو تسمم الكبد، أو الفشل الكبدي: </strong>اصفرار البشرة أو العينين، بول داكن، آلام في البطن، الغثيان، القيء، فقدان الشهية.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>قيء.</strong></p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>إسهال.</strong></p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>غثيان.</strong></p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>ألم في البطن.</strong></p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>حمى.</strong></p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">كمية بول أقل، تبول عدد مرات أقل.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>عدوى العين</strong>&nbsp;(التهاب الملتحمة): حكة/ احمرار العين مع إفرازات، وتورم.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">زيادة الدموع في العينينن، جفاف العينين.</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">تورم حول العينين أو في الجفون.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>غير شائعة.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>نزيف في المعدة أو الأمعاء: </strong>ألم شديد في البطن، قيء دموي، البراز الأسود أو الدموي، تورم البطن. الشعور بالدوخة أو الوهن، فقدان الوعي. ضيق التنفس.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>الثقب المعدي المعوي.</strong>&nbsp;(ثقب في جدار المعدة أو الأمعاء): آلام شديدة في البطن، غثيان، قيء، قشعريرة أو حمى.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>انخفاض أو زيادة مستوى البوتاسيوم في الدم: </strong>ضربات قلب غير منتظمة، ضعف العضلات، والشعور العام بعدم الارتياح.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>الداء الرئوي الخلالي.</strong>&nbsp;(مرض يسبب تهيج أنسجة الرئة أو تندبها): ضيق التنفس، التعب، السعال الجاف.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>الفشل التنفسي الحاد: </strong>تفاقم حاد لضيق التنفس، لون مزرق للبشرة والشفاه والأظافر، ضربات قلب غير منتظمة، الشعور بالنعاس، فقدان الوعي.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>انخفاض ضغط الدم: </strong>الدوخة، الإغماء، الدوار الخفيف.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">فقدان الوعي أو الإغماء.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">صعوبة السمع.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">دم في البول.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>اختلال وظيفة البطين الأيسر، فشل القلب الاحتقاني</strong> (ضعف القلب): التعب، تورم الكاحلين، ضيق التنفس خاصة عند الاستلقاء.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>نوبة قلبية </strong>(توقف تدفق الدم في جزء من القلب): ألم أو ضغط أو عدم راحة مفاجئ في الصدر، الشعور بفقدان الوعي، ضيق التنفس، احتمال عدم انتظام ضربات القلب.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>صدمة قلبية </strong>(عدم قدرة القلب على<strong> </strong>ضخ<strong> </strong>ما يكفي من الدماء لأعضاء الجسم):<strong> </strong>سرعة التنفس، سرعة ضربات القلب، فقدان الوعي، التعرق، شحوب البشرة، أيدٍ أو قدم باردة.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>ذبحة صدرية </strong>(عدم وصول أكسجين كافٍ لعضلة القلب): ألم أو ضغط في الصدر يحدث عادة أثناء ممارسة الرياضة أو الإجهاد البدني، ينتهي عند الراحة.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>متلازمة رينو: </strong>الشعور بالخدر والبرد في أصابع اليدين والقدمين، كاستجابة لبرودة درجة الحرارة أو للإجهاد.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>التهاب النسيج الخلوي </strong>(عدوى تحت الجلد): احمرار وسخونة وألم وتورم في المنطقة.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>متلازمة ضعف الحس الاحمراري الراحي الأخمصي: </strong>الاحمرار أو التورم في راحة اليدين وباطن القدمين. قد تشعر أيضًا بوخز أو ألم حارق.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>متلازمة تحلل الورم.</strong>&nbsp;الغثيان، أو ضيق التنفس، أو عدم انتظام ضربات القلب، أو بول عكر، أو التعب، أو ألم في المفاصل.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>نادرة.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>مشكلات بالعين:</strong>&nbsp;دم في العين، مشكلة في الرؤية، عدم وضوح الرؤية.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>التليف الرئوي </strong>(تندب في أنسجة الرئة): ضيق التنفس، التعب، السعال الجاف.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>نوبة صرع.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>حمامي عديدة الأشكال </strong>(رد فعل جلدي تحسسي): بقع جلدية حمراء أو أرجوانية، مع احتمالية وجود بثور أو قشرة في المنتصف. احتمالية التعرض لشفاه متورمة. حكة خفيفة أو حارقة.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>متلازمة ستيفنز جونسون، انحلال البشرة النخري السمي </strong>(رد فعل جلدي حاد): طفح جلدي، احمرار الجلد، بقع حمراء أو أرجوانية مع احتمالية وجود بثور أو قشور في المنتصف، طفح جلدي، تقشر الجلد، بثور على الشفاه، أو على العينين أو البشرة أو في الفم، حكة، حرقة، شعور مشابه للأنفلونزا، حمى.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>انحلال خلايا الدم الحمراء: </strong>بشرة شاحبة، الشعور بالتعب أو قصر النفس، بول داكن.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>تكرار غير معروف.</strong></p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>ردات فعل تحسسية: </strong>حكة، طفح، شرى، تورم الشفاه أو اللسان أو الحلق، صعوبة في البلع أو التنفس.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>تفاعل الدواء مع الحمضات والأعراض الجهازية </strong>(رد فعل شديد تجاه الدواء يشمل بشرتك وعضوًا أو أكثر من أعضائك. قد تظهر لديك بعض الآثار الجانبية المدرجة هنا): حمى، طفح شديد، تورم الغدد الليمفاوية، شعور يشبه الأنفلونزا، اصفرار البشرة أو العيون، ضيق التنفس، سعال جاف، ألم في الصدر أو الشعور بعدم الراحة، التبول أقل من المعتاد، كمية أقل من البول.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL"><strong>انحلال الربيدات</strong> (انحلال سريع للعضلات): ألم عضلي غير مبرر، الإيلام أو التعب، بول بني داكن.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>تجلط دموي في الأوعية الدموية:</strong>&nbsp;تورم واحمرار وألم في جزء واحد من الجسم.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>اضطراب أمراض النساء. (مشكلات في الجهاز التناسلي للمرأة): </strong>ألم في الجزء السفلي من البطن أو دم غير متوقع من المهبل أو حدوث كليهما.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>النخر اللاوعائيّ/ نخر رأس الفخد </strong>(تحلل أو انهيار أنسجة العظم): ألم وصعوبة أثناء المشي.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>الضعف الكلوي المزمن </strong>(انخفاض وظائف الكلى).</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>إعادة نشاط فيروس التهاب الكبد الفيروسي ب </strong>(عدوى فيروسية نشطة في الكبد): حمى، طفح جلدي، آلام المفاصل والتهاب، وتعب، وفقدان الشهية، الغثيان، اليرقان (اصفرار الجلد أو ابيضاض العينين)، ألم في الجزء الأيمن العلوي من البطن، براز شاحب، بول داكن.</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>هذه القائمة لا تشمل جميع الآثار الجانبية المحتملة التي قد تشعر بها عند تناول كيتوفا. في حال أزعجك عرض جانبي غير مدرج في هذه القائمة، فتحدث مع أخصائي الرعاية الصحية لديك. وفي حال ظهور عرض ما أو أثر جانبي يؤثر على أنشطتك اليومية، فتحدث مع أخصائي الرعاية الصحية لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احتفظ بهذا الدواء بعيدًا عن متناول ورؤية الأطفال.</li><li>يُحفظ الدواء في درجة حرارة لا تتجاوز 30 درجة مئوية.</li><li>لا تستخدم هذا الدواء بعد تاریخ انتهاء الصلاحية المدون على عبوة الدواء.&nbsp;</li><li>لا تستخدم أي عبوة دواء تالفة أو يبدو عليها علامات التلاعب.</li><li>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يطلق على المادة الفعالة في هذا الدواء ميسيلات الإيماتينيب.</li><li>المكونات الأخرى هي كروسبوفيدون، وستيرات المغنيسيوم، ثاني أكسيد السيليكون الغرواني، هيدروكسي بروبيل ميثيل سيللوز 2910، هيدروكسي بروبيل السليلوز، جليكولات نشا الصوديوم، أكسيد الحديد الأحمر الثلاثي، أكسيد الحديد الأصفر الثلاثي.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كيتوفا هي أقراص ذات لون برتقالي بني، مستديرة الشكل، محدبة على نحو طفيف، والأقراص المُغلفة محفور عليها كلمة &laquo;IMA&raquo; فوق درجة &laquo;100&raquo; على أحد جانبيها و &laquo; APO&raquo; على الجانب الآخر.<br />أقراص كيتوفا هي أقراص ذات لون برتقالي بني، ذات شكل كبسولي محدب، والأقراص المُغلفة محفور عليها كلمة &laquo;IMA&raquo; فوق درجة &laquo;400&raquo; على أحد جانبيها و &quot;APO&quot;&nbsp;على الجانب الآخر.</p><p>متوفر في زجاجات بحجم 30 ملجم و500 ملجم،<br />&nbsp;وعبوات شرائط تحتوي على &nbsp;۳۰ قرصًا مغلف (۳ شرائط بكل شریط ۱۰ أقراص)، وعبوات شرائط تحتوي على &nbsp;١٠۰ قرص مغلف (١٠ شرائط بكل شریط ۱۰ أقراص)</p><p>قد لا تتوافر جميع الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، تورونتو، أونتاریو، كندا. M9L 1T9<br />الھاتف: 4164017500<br />&nbsp;الفاكس: 4164013785<br />البرید الإلكتروني:&nbsp;support@apotex.com</p><p><br /><strong>للحصول على مزید من المعلومات عن ھذا المنتج الدوائي، برجاء التواصل مع ممثل صاحب الترخیص والتسویق المحلي:</strong><br />شركة أبوتكس &ndash; المملكة العربیة السعودیة<br />شارع التحلیة، جدة.<br />۰۰۹٦٦۱۲۲٦۳۱۹٦۰<br />aaldawoo@apotex.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KETOVA, Imatinib mesylate Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KETOVA (imatinib mesylate) Tablets 100 mg: Each brownish orange, slightly biconvex round film-coated tablet, engraved “IMA” over score “100” on one side and “APO” on the other side, contains 100 mg of imatinib. Available in bottles of 30 and 1000 as well as in blisters of 30 (3 x 10) and 100 (10 x 10).

KETOVA (imatinib mesylate) Tablets 400 mg: Each brownish orange, capsule shaped biconvex film-coated tablet, engraved “IMA” score “400” on one side and “APO” on the other side, contains 400 mg of imatinib. Available in bottles of 30 and 500 as well as in blisters of 30 (3 x 10) and 100 (10 x 10).

In addition to the active ingredient, imatinib mesylate, each tablet also contains the non- medicinal ingredients: colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, red ferric oxide, and yellow ferric oxide.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                100 mg: Each brownish orange, slightly biconvex round film-coated tablet, engraved “IMA” over score “100” on one side and “APO” on the other side.

400 mg: Each brownish orange, capsule shaped biconvex film-coated tablet, engraved “IMA” score “400” on one side and “APO” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>KETOVA (imatinib mesylate) is indicated for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.<ul><li>Clinical effectiveness in newly diagnosed CML was based on progression-free survival, hematologic and cytogenetic response rates (surrogate endpoints) that are reasonably likely to predict clinical benefit in a long-term randomized controlled study.</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA (imatinib mesylate) is indicated for the treatment of pediatric patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.<ul><li>Clinical effectiveness in newly diagnosed CML, was based on hematologic and cytogenetic response rates (surrogate endpoints) in a short-term uncontrolled study in which the majority of patients withdrew from protocol therapy to undergo hematopoietic stem cell transplantation.</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon- alpha therapy.<ul><li>Clinical effectiveness in Philadelphia chromosome-positive chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase (after failure of interferon-alpha therapy) was based on hematologic and cytogenetic response rates (surrogate endpoints), which have shown to be sustained for at least two years.</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).<ul><li>Clinical effectiveness for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) was based on hematologic response rates (surrogate endpoints).</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.<ul><li>Clinical effectiveness in adult patients with relapsed or refractory Ph+ ALL as monotherapy was based on hematologic and cytogenetic response rates (surrogate endpoints).</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet derived growth factor receptor (PDGFR) gene re- arrangements.<ul><li>Clinical effectiveness in adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re- arrangements was based on hematologic and cytogenetic response rates (surrogate endpoints).</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for the treatment of adult patients with aggressive sub- types of systemic mastocytosis (ASM and SM-AHNMD1) without the D816V c-Kit mutation. If c-Kit mutational status in patients with ASM or SM-AHNMD1 is not known or unavailable, treatment with KETOVA may be considered if there is no satisfactorily response to other therapies.<ul><li>Clinical effectiveness in adult patients with aggressive sub-types of systemic mastocytosis (ASM and SM-AHNMD1) without the D816V c-Kit mutation and in adult patients with ASM or SM-AHNMD1 where c-Kit mutational status is not known or unavailable, and if there is no satisfactory response to other therapies was based on hematologic response rates (surrogate endpoints).</li><li>1 ASM: Aggressive systemic mastocytosis; SM-AHNMD: Systemic mastocytosis with an associated clonal hematological non-mast-cell disorder.</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR&alpha; rearrangement.<ul><li>Clinical effectiveness in adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR&alpha; rearrangement was based on hematologic and cytogenetic response rates (surrogate endpoints).</li></ul></li></ul><p>&nbsp;</p><ul><li>KETOVA is also indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).<ul><li>Clinical effectiveness in adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) was based on objective response rate (surrogate endpoints).</li></ul></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Dosing</u></strong><strong><u> </u></strong><strong><u>Considerations</u></strong></p><p>Therapy should be administered under the supervision of a physician experienced in the treatment of patients with hematological malignancies and/or malignant sarcomas .</p><p>The prescribed dose should be administered orally, during a meal and with a large glass of water to minimize the risk of gastrointestinal disturbances. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day in the morning and in the evening. Efficacy data for the 800 mg/day dose are limited.</p><p>Dosing in pediatric patients should be on the basis of body surface area (mg/m2). Treatment can be given as a once daily dose or alternatively the daily dose may be split into two administrations &ndash; one in the morning and one in the evening. (See CLINICAL TRIALS SECTION AND ACTION AND CLINICAL PHARMACOLOGY SECTION). There is no experience with the use of imatinib mesylate in pediatric patients with CML under 2 years of age. There is very limited to no experience with the use of imatinib mesylate in children in other indications.</p><p>For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 mL for a 100 mg tablet, and 200 mL for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s). Traces of the disintegrated tablet left in the glass after drinking should also be consumed.</p><p>Treatment should be continued as long as the patient continues to benefit.</p><p>For daily dosing of 800 mg, KETOVA should be administered using the 400 mg tablet twice a day to reduce exposure to iron.</p><p>Preventative measures should be considered prior to treatment with KETOVA in patients with increased risk for TLS (see WARNINGS AND PRECAUTIONS and Monitoring and Laboratory Tests).</p><p>&nbsp;</p><p><strong>Recommended Dose and Dosage Adjustment</strong></p><p><u>Chronic myeloid leukemia (CML)</u></p><p>The recommended dosage of KETOVA is 400 mg/day for adult patients with newly diagnosed CML or in chronic phase CML. The recommended dosage for adult patients in accelerated phase or blast crisis is 600 mg/day. The recommended dosage of KETOVA for pediatric patients with newly diagnosed Ph+ CML is 340 mg/m2/day (rounded to the nearest 100 mg, i.e not to exceed 600 mg).</p><p>In CML, a dose increase from 400 mg to 600 mg or to 800 mg/day in adult patients with chronic phase disease, or from 600 mg to 800 mg (given as 400 mg twice daily) in adult patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reactions and severe non-leukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory hematologic response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved hematologic and/or cytogenetic response.</p><p>Patients with CML should undergo regular response monitoring (See WARNINGS AND PRECAUTIONS). Any changes to patient imatinib therapy (for example, when imatinib dose is lowered due to occurrence of side effects) should be followed by close response monitoring.</p><p>&nbsp;</p><p><u>Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)</u></p><p>The recommended dose of KETOVA for use as a single-agent for induction phase therapy in adult patients with newly diagnosed Ph+ALL, or for adult patients with relapsed or refractory Ph+ ALL is 600 mg/day.</p><p>&nbsp;</p><p><u>Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)</u></p><p>The recommended dose of KETOVA is 400 mg/day for adult patients with MDS/MPD</p><p>&nbsp;</p><p><u>Aggressive sub-types of Systemic Mastocytosis (ASM and SM-AHNMD)</u></p><p>The recommended dose of KETOVA is 400 mg/day for adult patients with ASM or SM- AHNMD without the D816V c-Kit mutation or mutational status unknown and not responding satisfactory to other therapies.</p><p>For patients with ASM or SM-AHNMD associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR&alpha;, a starting dose of 100 mg/day is recommended. A dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.</p><p>&nbsp;</p><p><u>Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)</u></p><p>The recommended dose of KETOVA is 100 mg/day for adult patients with HES/CEL.</p><p>For HES/CEL patients, a dose increase from 100 mg to 400 mg may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. Treatment should be continued as long as the patient continues to benefit.</p><p>&nbsp;</p><p><u>Dermatofibrosarcoma Protuberans (DFSP)</u></p><p>The recommended dose of KETOVA is 800 mg/day for adult patients with DFSP.</p><p>&nbsp;</p><p><u>Dose</u><u> </u><u>Adjustment </u><u>for</u><u> Hepatotoxicity and Other Non-Hematologic Adverse Drug Reactions</u></p><p>If a severe non-hematologic adverse drug reaction develops (such as severe hepatotoxicty or severe fluid retention), KETOVA should be withheld until the event has resolved. Thereafter, treatment can be resumed as appropriate depending on the initial severity of the event.</p><p>If elevations in bilirubin &gt;3 x institutional upper limit of normal (IULN) or in liver transaminases &gt;5 x IULN occur, KETOVA should be withheld until bilirubin levels have returned to a &lt;1.5 x IULN and transaminase levels to &lt;2.5 x IULN. In adults, treatment with KETOVA may then be continued at a reduced daily dose (i.e., from 400 mg to 300 mg or from 600 mg to 400 mg, or from 800 mg to 600 mg). In children, daily doses can be reduced under the same circumstances from 340 mg/m2/day to 260 mg/m2/day.</p><p>&nbsp;</p><p><u>Dose Adjustment for Patients with Hepatic Impairment</u></p><p>Patients with mild, and moderate liver dysfunction should be dosed at the minimum effective dose of 400 mg daily and patients with severe liver dysfunction should start at 200 mg daily. In the absence of severe toxicity, a dose increase up to 300 mg daily may be considered. The dose should be reduced if the patient develops unacceptable toxicity. (See ACTION AND CLINICAL PHARMACOLOGY).</p><p>&nbsp;</p><p><u>Dose Adjustment for Patients with Renal Impairment</u></p><p>Imatinib mesylate and its metabolites are not excreted via the kidney to a significant extent. However, it has been shown that exposure to imatinib is increased up to 2-fold in patients with mild (CrCL: 40-59 mL/min) and moderate (CrCL: 20-39 mL/min) renal dysfunction, and that there is a significant correlation in the incidence of serious adverse events with decreased renal function.</p><p>In clinical trials to date, the safety and efficacy of imatinib mesylate in patients with renal impairment has not been established. Patients with mild or moderate renal dysfunction should be treated with cautio n, and be given the minimum recommended effective dose of 400 mg daily as starting dose. (SEE ACTION AND CLINICAL PHARMACOLOGY) The dose should be reduced if not tolerable. If tolerated, the dose can be increased for lack of efficacy (See section WARNINGS AND PRECAUTIONS). Treatment of patients with moderate renal insufficiency at 800 mg cannot be recommended as this dose has not been investigated in these patients. The effect of imatinib mesylate treatment on patients with severe renal dysfunction (CrCL: &lt;20 mL/min) and on hemodialysis has not been assessed, so treatment of these patients with imatinib cannot be recommended.</p><p>&nbsp;</p><p><u>Hematologic adverse drug reactions</u></p><p>Dose reduction or treatment interruptions for severe neutropenia and thrombocytopenia are recommended as indicated in the table below.</p><p>&nbsp;</p><p>Dose adjustments for neutropenia and thrombocytopenia</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>ASM or SM-AHNMD associated with eosinophilia and HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase (starting dose 100 mg)</p></td><td><p>ANC &lt; 1.0 x10^9/L</p><p>and/or</p><p>platelets &lt; 50 x10^9/L</p></td><td><p>1.&nbsp; Stop KETOVA until ANC &ge; 1.5 x10^9/L and platelets &ge;</p><p>75 x10^9/L.</p><p>2.&nbsp; Resume treatment with KETOVA at previous dose (i.e. before severe adverse drug reaction).</p></td></tr><tr><td><p>Chronic phase CML (starting at dose 400 mg)</p><p><strong>&nbsp;</strong></p><p>MDS/MPD, ASM/SM- AHNMD, HES/CEL (at 400 mg dose)</p></td><td><p>ANC &lt; 1.0 x10^9/L</p><p>&nbsp;</p><p>and/or</p><p>Platelets &lt; 50 X 10^9/L</p></td><td><p>1.&nbsp; Stop KETOVA until ANC &ge;1.5 x10^9/L and platelets &ge; 75 x10^9/L.</p><p>2.&nbsp; Resume treatment with KETOVA at the original dose of 400 mg or 600 mg (i.e. before severe adverse drug reaction).</p><p>3.&nbsp; If recurrence of ANC &lt; 1.0 x10^9/L and/or Platelets</p><p>&lt; 50 x10^9/L, repeat step 1 and resume KETOVA at a reduced dose of 300 mg (if starting dose was 400 mg, 400 mg if starting dose was 600 mg).</p></td></tr><tr><td><p>Newly diagnosed pediatric chronic phase CML (at dose 340 mg/m^2/day)</p></td><td><p>ANC &lt; 1.0 x10^9/L</p><p>and/or</p><p>platelets &lt; 50 x10^9/L</p></td><td><p>1.&nbsp; Stop KETOVA until ANC &ge; 1.5 x10^9/L and platelets &ge;</p><p>75 x10^9/L.</p><p>2.&nbsp; Resume treatment with KETOVA at previous dose (i.e. before severe adverse drug reaction).</p><p>3.&nbsp; In the event of recurrence of ANC &lt; 1.0 x10^9/L and/or platelets &lt; 50 x10^9/L, repeat step 1 and resume KETOVA at reduced dose of 260 mg/m^2/day.</p></td></tr><tr><td><p>Accelerated phase CML and blast crisis and Ph+ALL (starting dose 600 mg)</p></td><td><p>(1) ANC &lt; 0.5 x10^9/L</p><p>and/or</p><p>Platelets &lt; 10 x10^9/L</p></td><td><p>1.&nbsp; Check if cytopenia is related to leukemia (marrow aspirate or biopsy).</p><p>2.&nbsp; If cytopenia is unrelated to leukemia, reduce dose of KETOVA to 400 mg.</p><p>3.&nbsp; If cytopenia persists for 2 weeks, reduce further to 300 mg.</p><p>4.&nbsp; If cytopenia persists for 4 weeks and is still unrelated to leukemia, stop KETOVA until ANC &ge; 1</p><p>x10^9/L and platelets &ge; 20 x10^9/L and then resume treatment at 300 mg.</p></td></tr><tr><td><p>DFSP</p><p>(at 800 mg dose)</p></td><td><p>ANC &lt; 1.0 x10^9/L</p><p>and/or</p><p>platelets &lt; 50 x10^9/L</p></td><td><p>1.&nbsp; Stop KETOVA until ANC &ge; 1.5 x10^9/L and platelets &ge;</p><p>75 x10^9/L.</p><p>2.&nbsp; Resume treatment with KETOVA at 600 mg.</p><p>3.&nbsp; In the event of recurrence of ANC &lt; 1.0 x10^9/L and/or platelets &lt; 50 x10^9/L, repeat step 1 and resume KETOVA at reduced dose of 400 mg.</p></td></tr><tr><td colspan="3"><p>ANC: absolute neutrophil count</p><p>(1) occurring after at least 1 month of treatment</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KETOVA (imatinib mesylate) is contraindicated in patients with hypersensitivity to imatinib or to any other component of KETOVA.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p>&nbsp;</p><p><strong>Effects</strong><strong> </strong><strong>on </strong><strong>ability to drive and use machines</strong></p><p>Reports of motor vehicle accidents have been received in patients receiving imatinib mesylate. Caution should be recommended when driving a car or operating machinery (see Undesirable effects from Post-Marketing reports section and Drug-Lifestyle Interactions section).</p><p>&nbsp;</p><p><strong>Tumour Lysis Syndrome (TLS):</strong></p><p>Tumour lysis syndrome has occurred in patients taking imatinib mesylate, including fatal cases (see &ldquo;Undesirable effects from Post-marketing Reports&rdquo;). Patients at increased risk for TLS include those with tumours having a high proliferative rate (e.g. CML-blast crisis), concomitant chemotherapy or radiotherapy or having a solid tumour of large size (bulky disease), decreased kidney function or elevated lactate dehydrogenase (LDH) at baseline.</p><p>Preventative measures, including correction of clinically significant dehydration and treatment of high uric acid levels, should be considered for patients at increased risk of developing TLS (see DOSAGE AND ADMINISTRATION and Monitoring and Laboratory Tests).</p><p>&nbsp;</p><p><strong><u>Carcinogenesis and Mutagenesis</u></strong></p><p>A 2-year preclinical carcinogenicity study conducted in rats demonstrated renal adenomas/carcinomas, urinary bladder and urethra papillomas, papillomas/carcinomas of the preputial and clitoral gland, adenocarcinomas of the small intestine, adenomas of the parathyroid glands, benign and malignant tumors of the adrenal medulla and papillomas/carcinomas of the nonglandular stomach (See TOXICOLOGY).</p><p>Long-term, non-neoplastic histological changes identified in the preclinical carcinogenicity study in rats include cardiomyopathy.</p><p>The relevance of these findings in the rat carcinogenicity study for humans is not known. An analysis of the clinical safety data from clinical trials and spontaneous adverse event reports did not provide evidence of an increased overall incidence of malignancies in patients treated with imatinib mesylate compared to that of the general population.</p><p>However, adverse events in cancer patients are significantly under reported and a large proportion of patients treated with imatinib mesylate have had limited follow-up thus not permitting a final analysis of the potential for an increased incidence of a secondary malignancy in patients treated with imatinib mesylate.</p><p>&nbsp;</p><p><strong><u>Cardiovascular</u></strong></p><p>Severe congestive heart failure (CHF) and reduction of left ventricular ejection fraction (LVEF) have been reported in patients taking imatinib mesylate. Although several of these patients had preexisting conditions including hypertension, diabetes and prior coronary artery disease, they were subsequently diagnosed with CHF. Patients with known cardiac disease or risk factors for cardiac failure should be monitored carefully and those with symptoms or signs consistent with CHF should be evaluated and treated. In patients with history of cardiac disease or in elderly patients, a baseline evaluation of LVEF is recommended prior to initiation of KETOVA therapy.</p><p>&nbsp;</p><p>In patients with hypereosinophilic syndrome (HES) with occult or known infiltration of HES cells within the myocardium, isolated cases of cardiogenic shock/left ventricular dysfunction believed to be associated with HES &nbsp;&nbsp;cell degranulation upon initiation of imatinib mesylate therapy, have been reported. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding imatinib mesylate. Myelodysplastic/myeloproliferative diseases (MDS/MPD) and systemic mastocytosis (SM) might be associated with high eosinophil levels. Performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL and in patients with MDS/MPD or ASM and SM-AHNMD associated with high eosinophil levels. These patients with HES/CEL or ASM, SM-AHNMD and MDS/MPD must be also on 1-to 2 mg/kg of prednisone equivalent oral steroids for one to two weeks, initiated at least 2 days prior to beginning KETOVA therapy.</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong></p><p>Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib mesylate. Thyroid-Stimulating Hormone levels should be closely monitored in such patients.</p><p>&nbsp;</p><p><strong><u>Fluid Retention and edema</u></strong></p><p>Imatinib mesylate is often associated with edema and occasionally serious fluid retention (see Adverse Reactions Table 1 and 2). All Grades of fluid retention/edema were reported in up to 61.7% for newly diagnosed CML patients, up to 76.2% for other CML patients across all clinical trials. Patients should be weighed and monitored regularly for signs and symptoms of fluid retention as fluid retention can occur after months of treatment. An unexpected rapid weight gain should be carefully investigated and appropriate treatment provided. The probability of edema was increased with higher imatinib dose. Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib mesylate and in 2.1% to 5.8% of other adult CML patients taking imatinib mesylate. In addition, other severe fluid retention events (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) were reported in 1.3% of newly diagnosed CML patients taking imatinib mesylate and in 1.7% to 6.2% of other adult CML patients taking imatinib mesylate.</p><p>&nbsp;</p><p><strong><u>Gastrointestinal</u></strong></p><p>Hemorrhage: See &ldquo;Hemorrhage&rdquo; below.</p><p>Imatinib mesylate is sometimes associated with GI irritation. KETOVA should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of gastrointestinal perforation.</p><p>&nbsp;</p><p><strong><u>Hematologic</u></strong></p><p>Hematologic Toxicity: Treatment with imatinib mesylate is often associated with neutropenia or thrombocytopenia (See Undesirable effects, Tables 6 to 8). Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example every 2-3 months). The occurrence of these cytopenias is dependent on the stage of disease and is more frequent in patients with accelerated phase CML or blast crisis than in patients with chronic phase CML. In pediatric CML patients the most frequent toxicities observed were Grade 3 or 4 cytopenias involving neutropenia (31%), thrombocytopenia (16%) and anemia (14%). These generally occur within the first several months of therapy (See DOSAGE AND ADMINISTRATION).</p><p>An increased rate of opportunistic infections was observed in a monkey study with chronic imatinib treatment. In a 39-week monkey study, treatment with imatinib resulted in worsening of normally suppressed malarial infections &nbsp;in these animals. Lymphopenia was observed in animals (as in humans, where all grades of lymphopenia were observed in 0.3% patients).</p><p>&nbsp;</p><p><strong><u>Hemorrhage</u></strong></p><p>All Grades of hemorrhage were reported in up to 28.9% for newly diagnosed CML patients, up to 53% for other CML patients across all clinical trials.</p><p>In the newly diagnosed CML trial, 1.8% of patients had Grades 3 /4 hemorrhage.</p><p>Subdural hematomas have been reported in association with imatinib administration in patients with other contributing factors, including older age (eg., Age greater than 50-55 years); thrombocytopenia due to the underlying malignancy or concomitant administration of multi- agent chemotherapy; concomitant administration of medications that increase bleeding risk; and prior lumbar puncture or head trauma. In clinical trials, the incidence of subdural hematoma has ranged from 0 to 2.4%.</p><p>This risk of bleeding should be evaluated carefully in all patients. Caution should be exercised with the concomitant use of antiplatelet agents or warfarin, especially in patients who are thrombocytopenic. Platelet counts and prothrombin time should be measured on a regular basis when imatinib is used concurrently with anticoagulants, prostacyclins, or other medications that increase bleeding risk. Patients should be monitored for gastrointestinal symptoms at the start of therapy and during the treatment. Patients who experience head trauma or have unexplained neurological symptoms should be evaluated for subdural hematoma. In view of a potential interaction between imatinib mesylate and warfarin leading to increased exposure to warfarin, patients who require anticoagulation with warfarin should be monitored especially closely when imatinib mesylate dose adjustments are necessary (see DRUG INTERACTIONS).</p><p>&nbsp;</p><p><strong><u>Hepatic/Biliary/Pancreatic</u></strong></p><p>Liver failure: There have been cases of cytolytic and cholestatic hepatitis and hepatic failure; in some cases the outcome was fatal. One patient, who was taking acetaminophen regularly for fever along with imatinib mesylate, died of acute liver failure (see DRUG INTERACTIONS).</p><p>Hepatotoxicity: Hepatotoxicity, occasionally severe, may occur with KETOVA (see Undesirable effects Tables 1 and 2). Liver function (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment and monthly or as clinically indicated. Laboratory abnormalities should be managed with interruption and/or dose reduction of the treatment with KETOVA. (See sections Undesirable effects and DOSAGE AND ADMINISTRATION). Patients with hepatic impairment should be closely monitored. Although pharmacokinetic analysis results showed there is considerable inter-subject variation, the mean exposure to imatinib did not differ significantly between patients with mild and moderate liver dysfunction (as measured by dose normalized AUC) and patients with normal liver function. Patients with severe liver dysfunction demonstrated increased exposure to imatinib and its active metabolite CGP 74588. Liver function monitoring remains crucial as no long term toxicity and tolerability have been established (See CLINICAL PHARMACOLOGY).</p><p>Hepatotoxicity has been observed in patients treated with imatinib mesylate. All Grades of liver toxicity (including liver failure) were reported in up to 11.6% for newly diagnosed CML patients, up to 12% for other CML patients across all clinical trials.</p><p>&nbsp;</p><p><strong><u>Hepatitis B reactivation </u></strong></p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.</p><p>Patients should be tested for HBV infection before initiating treatment with imatinib mesylate. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with imatinib mesylate should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).</p><p>&nbsp;</p><p><strong><u>Toxicities From Long-Term Use:</u></strong></p><p>It is important to consider potential toxicities suggested by animal studies, specifically, liver, kidney and cardiac toxicity and immunosuppression. Liver toxicity was observed in rats, dogs and cynomolgus monkeys in repeated dose studies. Most severe toxicity was noted in dogs and included elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia.</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p>Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralization and dilation of the renal tubules and tubular nephrosis. Increased BUN and creatinine were observed in several of these animals.</p><p>Imatinib mesylate and its metabolites are not excreted via the kidney to a significant extent. Creatinine clearance (CrCL) is known to decrease with age, and age did not significantly affect imatinib kinetics.</p><p>In patients with impaired renal function, imatinib mesylate plasma exposure is higher (1.5- to 2- fold increase) than in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in patients with renal dysfunction. As well, there is a significant correlation in the incidence of serious adverse events with decreased renal function (p=0.0096). Patients with mild or moderate &nbsp;renal impairment should be treated with cautio n (see DOSAGE AND ADMINISTRATION). Since the effect of imatinib mesylate treatment on patients with severe renal dysfunction or on dialysis has not been sufficiently &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;assessed, recommendations on the treatment of these patients with KETOVA cannot be made. Patients with history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with &nbsp;renal failure should be evaluated and treated.</p><p>&nbsp;</p><p><strong><u>Respiratory</u></strong></p><p>Pulmonary events: Rare cases of pulmonary fibrosis and interstitial pneumonitis have been reported in patients who have received imatinib mesylate. However, no definitive relationship has been established between the occurrence of these pulmonary events and treatment with imatinib mesylate.</p><p>&nbsp;</p><p><strong><u>Skin</u></strong></p><p>Skin and Mucosa: Although rare, Erythema multiforme (EM), Toxic epidermal Necrolysis (TEN), and Stevens Johnson syndrome (SJS) have been reported in patients who have received imatinib mesylate. Skin biopsies in some cases of exfoliative skin rash associated with imatinib mesylate use have shown a mixed cellular infiltrate characteristic of a toxic drug reaction. Severe cases of exfoliative rash may require treatment interruption or discontinuation.</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), a potentially life-threatening syndrome including fever, severe skin eruption, lymphadenopathy, hematologic abnormalities (eosinophilia or atypical lymphocytes), and internal organ involvement, has also been reported in imatinib-treated patients. DRESS regressed when imatinib mesylate was discontinued, and in all cases where the drug was re-introduced, DRESS recurred. If DRESS occurs, KETOVA should be interrupted, and permanent discontinuation should be considered.</p><p>&nbsp;</p><p><strong><u>Special Populations:</u></strong></p><p><strong>Pediatrics:</strong></p><p>There is no experience with the use of imatinib mesylate in pediatric patients with CML under 2 years of age. There is very limited to no experience with the use of imatinib mesylate in children in other indications.</p><p>There have been case reports and series demonstrating growth retardation in children and pre- adolescents receiving imatinib mesylate. No prospective studies have been carried out in this regard and the long term effects of prolonged treatment with imatinib mesylate on growth in children are unknown. In a juvenile toxicology study, transitory decreases in crown to rump length were observed (between days 17 and 52 post-partum) in rats administered approximately 2X the highest recommended human pediatric dose of 340 mg/m2. At this dose, shortened tibia and femur lengths were non-reversible in female rats while a trend towards reversibility was seen in male rats (see TOXICOLOGY, Juvenile Developmental Toxicology). Another study demonstrated that rats administered imatinib resulted in premature growth plate closure (see</p><p>Vandyke et al.).Therefore, close monitoring of growth in children under KETOVA is highly recommended (see Undesirable effects).</p><p>&nbsp;</p><p><strong>Geriatrics:</strong></p><p>In the CML phase II studies, approximately 20% of patients were older than 65 years. The efficacy of imatinib mesylate was similar in all age groups studied.</p><p>&nbsp;</p><p><strong><u>Monitoring and Laboratory tests:</u></strong></p><p>Patients with known cardiac disease or risk factors for cardiac failure should be monitored carefully and those with symptoms or signs consistent with CHF should be evaluated and treated. In patients with history of cardiac disease or in elderly patients, a baseline evaluation of LVEF is recommended prior to initiation of KETOVA therapy. (see Cardiovascular).</p><p>For patients receiving KETOVA, complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example every 2-3 months) (see Hematologic, and DOSAGE and ADMINISTRATION).</p><p>Liver function (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment and monthly or as clinically indicated (see Hepatic/Biliary/Pancreatic, and DOSAGE and ADMINISTRATION).</p><p>Patients should be weighed and monitored regularly for signs and symptoms of fluid retention as fluid retention can occur after months of treatment with KETOVA (see Fluid Retention and edema).</p><p>Thyroid-Stimulating Hormone (TSH) levels should be closely monitored in thyroidectomy patients undergoing levothyroxine replacement during treatment with KETOVA (see Endocrine and Metabolism).</p><p>Signs and symptoms consistent with tumour lysis syndrome (e.g. hyperuricemia, hyperkalemia, hypocalcemia, hyperphosphatemia, acute renal failure, elevated LDH, high fevers) should be monitored at baseline and during initial treatment with KETOVA (see Tumour Lysis Syndrome (TLS) and DOSAGE AND ADMINISTRATION).</p><p>Close monitoring of growth in children under KETOVA treatment is highly recommended (See Special Populations, Pediatrics).</p><p>During treatment with KETOVA, serum electrolytes should be regularly monitored for possible hypophosphatemia, hyperkalemia, and hyponatremia in all patients as well as glucose, blood urea nitrogen (BUN) and creatinine. In addition, in pediatric patients, serum calcium and albumin should also be regularly monitored. Grades 3 /4 hypophosphatemia have been observed in 16.5% (15% Grade 3 and 1.5% Grade 4) of patients in a phase I dose finding study 03001 (N=143) and a phase II study 0102 (N=260) of chronic myeloid leukemia in blast crisis.</p><p>In patients with CML, regular response monitoring, particularly when therapy is modified, is essential to detect early signs of loss of response so that appropriate actions can be taken to avoid disease progression. A loss of response can occur at any time, but is more likely when imatinib treatment is modified (See DOSAGE AND ADMINISTRATION).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Drug-Drug</u></strong><strong><u> </u></strong><strong><u>Interactions</u></strong></p><p>&nbsp;</p><p><strong>Drugs</strong><strong> </strong><strong>that</strong><strong> </strong><strong>may</strong><strong> </strong><strong>alter</strong><strong> </strong><strong>imatinib</strong><strong> </strong><strong>plasma</strong><strong> </strong><strong>concentrations</strong></p><p><strong>&nbsp;</strong></p><p><u>Drugs that may increase imatinib plasma concentrations:</u></p><p>Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations. There was a significant increase in exposure to imatinib (mean Cmax and AUC of imatinib increased by 26% and 40%, respectively) in healthy subjects when imatinib mesylate was co-administered with a single dose of ketoconazole (CYP3A4 inhibitor). Caution is recommended when administering KETOVA with inhibitors of the CYP3A4 family (e.g. ketoconazole, erythromycin, clarithromycin, itraconazole, grapefruit juice).</p><p>&nbsp;</p><p><u>Drugs that may decrease imatinib plasma concentrations:</u></p><p>Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations. Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or St. John&rsquo;s Wort) may significantly reduce exposure to KETOVA.</p><p>Administration of rifampin 600 mg daily for eight days to 14 healthy adult volunteers, followed by a single 400 mg dose of imatinib mesylate increased imatinib oral dose clearance by 3.8-fold (90% CI 3.5- to 4.3-fold). Mean Cmax, AUC0-24 and AUC0-&infin; decreased by 54%, 68% and 74%, respectively compared to treatment without rifampin.</p><p>Similar results were observed in patients with malignant gliomas treated with imatinib mesylate while taking enzyme-inducing anti-epileptic drugs (EIAEDs) such as carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, and primidone. The plasma AUC for imatinib decreased by 73% compared to patients not on EIADs.</p><p>In two published studies, concomitant administration of imatinib mesylate and a product containing St. John&rsquo;s wort led to a 30-32% reduction in the AUC of imatinib mesylate. In patients in whom rifampin or other CYP3A4 inducers are indicated, alternate therapeutic agents with less enzyme induction potential should be considered.</p><p>Drugs that may have their plasma concentration altered by KETOVA</p><p>There is limited data on drug interactions. Since the major metabolic pathway is CYP3A4 mediated and KETOVA is an inhibitor of CYP2D6, precaution should be exercised with the co-administration of the following classes of drugs.</p><p>&nbsp;</p><p><strong>Table 9: Common classes of drugs used in patients with CML</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><strong>CYP3A4</strong></p></td><td colspan="2"><p><strong>CYP2D6</strong></p></td></tr><tr><td><p><strong>Inhibitors</strong></p></td><td><p><strong>Inducers</strong></p></td><td><p><strong>Substrates</strong></p></td><td><p><strong>Inhibitors</strong></p></td><td><p><strong>Substrates</strong></p></td></tr><tr><td><p>Cyclosporine Imidazo le</p><p>antifungals Macrolide antibiotics</p><p>Metronidazo le</p></td><td><p>Ant iepileptics Glucocorticoids Rifampicin</p><p>St. John&rsquo;s wort</p></td><td><p>Busulphan</p><p>Calcium-channel blockers Cyclophosphamide Cyclosporine Doxorubicin Epipodophyllotoxins Glucocorticoids Ifosphamide</p><p>Imidazo le antifungals Macrolide antibiotics (Azithromycin,</p><p>Clarithromycin, Erythromycin) PPIs</p><p>Retinoic acid Rifampicin Serotonin-H3 antagonists Vinca alkaloids</p></td><td><p>Dextropropoxyphene Doxorubicin Quinidine</p><p>Vinca alkaloids</p></td><td><p>Cyclophosphamide Beta blockers Morphine Oxycodone Serotonin-H3 antagonists</p></td></tr></tbody></table><p>&nbsp;</p><p>Imatinib mesylate increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5- fold, respectively, suggesting an inhibition of the CYP3A4 by imatinib mesylate. Therefore, caution is recommended when administering KETOVA with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide), (See Undesirable effects.)</p><p>In vitro, imatinib mesylate inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity. Imatinib at 400 mg twice daily had a weak inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23%. Caution is advised for CYP2D6 substrates with a narrow therapeutic window such as metoprolol. In patients treated with KETOVA and metoprolol clinical monitoring should be considered.</p><p>In vitro data suggest that imatinib mesylate has some capacity to act as an inhibitor of CYP2C9, although at concentrations higher than would be expected in plasma with recommended doses.</p><p>However, caution should be exercised with the concomitant use of drugs metabolized by CYP2C9 (e.g. warfarin). &nbsp;In view of the potential interaction between imatinib mesylate and warfarin, the international normalised ratio (INR) of patients who require anticoagulation with warfarin should be monitored closely, especially when KETOVA dose adjustments are necessary. Consideration should be given to anticoagulation with low-molecular weight heparin or unfractionated heparin.</p><p>In vitro, imatinib mesylate inhibits acetaminophen O-glucuronidation metabolic pathway with Ki value of 58.5 &mu;mol/L. Based on the in vitro results, systemic exposure to acetaminophen would be expected to increase when co-administered with imatinib mesylate. A clinical study showed that co-administration of imatinib mesylate (400 mg/day between days two and eight) in the presence of single dose acetaminophen (1000 mg/day on day eight) in CML patients did not alter the pharmacokinetics of acetaminophen. Imatinib mesylate pharmacokinetics was also not altered in the presence of single-dose acetaminophen. However, there are no pharmacokinetic or safety data on the concomitant use of imatinib mesylate at doses &gt; 400 mg/day or the chronic use of concomitant acetaminophen and imatinib mesylate. Hence CAUTION is recommended in patients on the concomitant use of KETOVA with acetaminophen.</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>There were no clinically relevant differences in absorption when imatinib mesylate was administered either with food or in the fasting state. The concomitant use of grapefruit juice should be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects on Fertility</strong></p><p>Stem cell factor and c-Kit genes are known to be important for germ cell development. Human studies on male patients receiving imatinib mesylate and its effect on male fertility and spermatogenesis have not been performed. However, clinical evidence of profound oligospermia with imatinib mesylate use has been reported in the literature as has clinical evidence for maintained male fertility. There is also pre-clinical evidence of impaired spermatogenesis without a reduction in fertility (See TOXICOLOGY). Therefore, physicians should advise and counsel their male patients as appropriate.</p><p>&nbsp;</p><p><strong>Use in Pregnancy</strong></p><p>Teratogenicity has been observed in animals studies (See TOXICOLOGY). There are no clinical trials on the use of imatinib mesylate in pregnant women. There have been post-market reports of spontaneous abortions and infant congenital anomalies from women who have taken imatinib mesylate. Imatinib is teratogenic in animals, &nbsp;therefore, KETOVA should not be administered to pregnant women. If it is used during pregnancy the patient should be apprised of the potential risk to the fetus. Women of childbearing potential must be advised to use highly effective birth control during treatment. Highly effective contraception is a method of birth control which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>In animals, imatinib and/or its metabolites were extensively excreted in milk. Both imatinib and its active metabolite can be distributed into human milk. There are two known cases of imatinib exposure during lactation. Their analysis shows the following results: the milk: plasma ratio was determined to be 0.5 for imatinib and 0.9 for the metabolite. Since the effects of exposure of the infant to imatinib are potentially serious, women taking KETOVA should not breast feed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects</strong><strong> </strong><strong>on </strong><strong>ability to drive and use machines</strong></p><p>Reports of motor vehicle accidents have been received in patients receiving imatinib mesylate.</p><p>Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with KETOVA. Therefore, caution should be recommended when driving a car or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Reaction </u></strong><strong><u>Overview</u></strong></p><p>Imatinib mesylate was generally well tolerated across all studies in CML. Complications of advanced malignancies and co-administered medications make causality of adverse events difficult to assess in single arm studies. The majority of imatinib mesylate treated patients experienced adverse events at some time.</p><p>Recent published literature revealed cases of musculoskeletal pain symptoms occurring upon imatinib discontinuation following long-term treatment, with a high frequency of 18% to 46% in CML patients. Those events may persist for months and were referred to as imatinib withdrawal symptoms (IWS).</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p>&nbsp;</p><p><strong>Chronic</strong><strong> </strong><strong>Myeloid Leukemia</strong></p><p>Imatinib mesylate was generally well tolerated with chronic oral daily dosing in patients with CML including pediatric patients. The majority of patients experienced adverse events at some point in time, however, most events were of mild to moderate Grade. In adult clinical trials, drug discontinuation for drug-related adverse events was observed in 2.4% of newly diagnosed patients, in 5 % of patients in chronic phase, 8% in accelerated phase and 9% in blast crisis.</p><p>The most frequently reported drug-related adverse events were fluid retention (superficial edema and other fluid retention events), nausea, vomiting, diarrhea, muscle cramps, fatigue and rash (Refer to Table 1 and 2 for newly diagnosed CML and other CML patients, respectively). Superficial edemas were a common finding in all studies described primarily as periorbital edemas or lower limb edemas. However, these edemas were rarely severe and may be managed with diuretics, other supportive measures, or by reducing the dose of imatinib mesylate tablets. (See DOSAGE AND ADMINISTRATION.)</p><p>Other adverse events such as pleural effusion, ascites, pulmonary edema and rapid weight gain with or without superficial edema may be collectively described as &ldquo;other fluid retention events&rdquo;.</p><p>These events were usually managed by withholding imatinib mesylate treatment temporarily and/or with diuretics and/or other appropriate supportive care measures. However, a few of these events may be serious or life threatening and several patients with blast crisis died with a complex clinical history of pleural effusion, congestive heart failure and renal failure. The following tables list the adverse experiences which occurred in &ge; 10% of patients in the clinical trials, regardless of relationship to therapy.</p><p>&nbsp;</p><p><strong>Table 1: Adverse experiences Regardless of Relationship to Study Drug reported in newly diagnosed CML (&ge;10% of all patients)(1)</strong></p><table border="2" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Adverse</strong><strong> </strong><strong>event</strong><strong> </strong><strong>(preferred</strong><strong> </strong><strong>term)</strong></p></td><td colspan="2"><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td colspan="2"><p><strong>CTC</strong><strong> </strong><strong>Grades</strong><strong> </strong><strong>3/4</strong></p></td></tr><tr><td><p><strong>Imatinib</strong><strong> </strong><strong>mesylate</strong><strong> </strong><strong>N=551</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td><p><strong>IFN+Ara&minus;C</strong><strong> </strong><strong>N=533</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td><p><strong>Imatinib</strong><strong> </strong><strong>mesylate</strong><strong> </strong><strong>N=551</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td><p><strong>IFN+Ara&minus;C</strong><strong> </strong></p><p><strong>N=533</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>Any</strong><strong> </strong><strong>event</strong></p></td><td><p><strong>99.1</strong></p></td><td><p><strong>99.6</strong></p></td><td><p><strong>57.2</strong></p></td><td><p><strong>77.3</strong></p></td></tr><tr><td><p><strong>Gastrointestinal</strong><strong> </strong><strong>Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>49.5</p></td><td><p>61.5</p></td><td><p>1.3</p></td><td><p>5.1</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>45.4</p></td><td><p>43.3</p></td><td><p>3.3</p></td><td><p>3.2</p></td></tr><tr><td><p>Abdo minal pain</p></td><td><p>36.5</p></td><td><p>25.9</p></td><td><p>4.2</p></td><td><p>3.9</p></td></tr><tr><td><p>Vomiting</p></td><td><p>22.5</p></td><td><p>27.8</p></td><td><p>2.0</p></td><td><p>3.4</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>18.9</p></td><td><p>8.3</p></td><td><p>0</p></td><td><p>0.8</p></td></tr><tr><td><p>Constipation</p></td><td><p>11.4</p></td><td><p>14.4</p></td><td><p>0.7</p></td><td><p>0.2</p></td></tr><tr><td><p>Dry mouth</p></td><td><p>2.9</p></td><td><p>10.9</p></td><td><p>0</p></td><td><p>0.2</p></td></tr><tr><td><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> </strong><strong>and administration site conditions</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fluid retention</p></td><td><p>61.7</p></td><td><p>11.1</p></td><td><p>2.5</p></td><td><p>0.9</p></td></tr><tr><td><p>&minus; Superficial edema</p></td><td><p>59.9</p></td><td><p>9.6</p></td><td><p>1.5</p></td><td><p>0.4</p></td></tr><tr><td><p>&minus; Other fluid retention events</p></td><td><p>6.9</p></td><td><p>1.9</p></td><td><p>1.3</p></td><td><p>0.6</p></td></tr><tr><td><p>Fatigue</p></td><td><p>38.8</p></td><td><p>67.0</p></td><td><p>1.8</p></td><td><p>25.1</p></td></tr><tr><td><p>Pyrexia</p></td><td><p>17.8</p></td><td><p>42.6</p></td><td><p>0.9</p></td><td><p>3.0</p></td></tr><tr><td><p>Rigors</p></td><td><p>9.3</p></td><td><p>34.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td></tr><tr><td><p>Asthenia</p></td><td><p>8.0</p></td><td><p>16.9</p></td><td><p>0.2</p></td><td><p>3.8</p></td></tr><tr><td><p>Influenza like illness</p></td><td><p>7.3</p></td><td><p>15.9</p></td><td><p>0</p></td><td><p>0.9</p></td></tr><tr><td><p>Mucosal Inflammation</p></td><td><p>1.1</p></td><td><p>10.3</p></td><td><p>0</p></td><td><p>3.2</p></td></tr><tr><td><p><strong>Hepatobiliary</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Liver toxicity (including liver failure)</p></td><td><p><strong>&nbsp;</strong></p><p>11.6</p></td><td><p><strong>&nbsp;</strong></p><p>17.3</p></td><td><p><strong>&nbsp;</strong></p><p>4.0</p></td><td><p><strong>&nbsp;</strong></p><p>5.1</p></td></tr><tr><td><p><strong>Infections</strong><strong> </strong><strong>and infestations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nasopharyngitis</p></td><td><p>30.5</p></td><td><p>8.8</p></td><td><p>0</p></td><td><p>0.4</p></td></tr><tr><td><p>Upper respiratory tract infection</p></td><td><p>21.2</p></td><td><p>8.4</p></td><td><p>0.2</p></td><td><p>0.4</p></td></tr><tr><td><p>Influenza</p></td><td><p>13.8</p></td><td><p>6.2</p></td><td><p>0.2</p></td><td><p>0.2</p></td></tr><tr><td><p>Sinusitis</p></td><td><p>11.4</p></td><td><p>6.0</p></td><td><p>0.2</p></td><td><p>0.2</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Weight increased</p></td><td><p>15.6</p></td><td><p>2.6</p></td><td><p>2.0</p></td><td><p>0.4</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;Adverse<strong> </strong>event</strong><strong> </strong><strong>(preferred</strong><strong> </strong><strong>term)</strong></p></td><td colspan="2"><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td colspan="2"><p><strong>CTC</strong><strong> </strong><strong>Grades</strong><strong> </strong><strong>3/4</strong></p></td></tr><tr><td><p><strong>Imatinib</strong><strong> </strong><strong>mesylate</strong><strong> </strong></p><p><strong>N=551</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td><p><strong>IFN+Ara&minus;C</strong><strong> </strong></p><p><strong>N=533</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td><p><strong>Imatinib</strong><strong> </strong><strong>mesylate</strong><strong> </strong></p><p><strong>N=551</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td><p><strong>IFN+Ara&minus;C</strong><strong> </strong></p><p><strong>N=533</strong><strong> </strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p>Weight decreased</p></td><td><p>5.1</p></td><td><p>17.3</p></td><td><p>0.4</p></td><td><p>1.3</p></td></tr><tr><td><p><strong>Metabolic</strong><strong> </strong><strong>and nutritional disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anorexia</p></td><td><p>7.1</p></td><td><p>31.7</p></td><td><p>0</p></td><td><p>2.4</p></td></tr><tr><td><p><strong>Musculoskeletal&amp; connective tissue disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle cramps</p></td><td><p>49.2</p></td><td><p>11.8</p></td><td><p>2.2</p></td><td><p>0.2</p></td></tr><tr><td><p>Musculoskeletalpain</p></td><td><p>47.0</p></td><td><p>44.8</p></td><td><p>5.4</p></td><td><p>8.6</p></td></tr><tr><td><p>Joint pain</p></td><td><p>31.4</p></td><td><p>38.1</p></td><td><p>2.5</p></td><td><p>7.7</p></td></tr><tr><td><p>Myalgia</p></td><td><p>24.1</p></td><td><p>38.8</p></td><td><p>1.5</p></td><td><p>8.3</p></td></tr><tr><td><p>Bone pain</p></td><td><p>11.3</p></td><td><p>15.6</p></td><td><p>1.6</p></td><td><p>3.4</p></td></tr><tr><td><p><strong>Nervous</strong><strong> </strong><strong>system disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Headache</p></td><td><p>37.0</p></td><td><p>43.3</p></td><td><p>0.5</p></td><td><p>3.8</p></td></tr><tr><td><p>Dizziness</p></td><td><p>19.4</p></td><td><p>24.4</p></td><td><p>0.9</p></td><td><p>3.8</p></td></tr><tr><td><p><strong>Psychiatric</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Depression</p></td><td><p>14.9</p></td><td><p>35.8</p></td><td><p>0.5</p></td><td><p>13.1</p></td></tr><tr><td><p>Insomnia</p></td><td><p>14.7</p></td><td><p>18.6</p></td><td><p>0</p></td><td><p>2.3</p></td></tr><tr><td><p>Anxiet y</p></td><td><p>9.6</p></td><td><p>11.8</p></td><td><p>0.5</p></td><td><p>2.6</p></td></tr><tr><td><p><strong>Respiratory</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cough</p></td><td><p>20.0</p></td><td><p>23.1</p></td><td><p>0.2</p></td><td><p>0.6</p></td></tr><tr><td><p>Pharyngo laryngeal pain</p></td><td><p>18.1</p></td><td><p>11.4</p></td><td><p>0.2</p></td><td><p>0</p></td></tr><tr><td><p>Dyspnea</p></td><td><p>9.3</p></td><td><p>14.4</p></td><td><p>1.8</p></td><td><p>1.7</p></td></tr><tr><td><p><strong>Skin</strong><strong> </strong><strong>and subcutaneous disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash and related terms</p></td><td><p>40.1</p></td><td><p>26.1</p></td><td><p>2.9</p></td><td><p>2.4</p></td></tr><tr><td><p>Night sweats</p></td><td><p>9.8</p></td><td><p>15.8</p></td><td><p>0.2</p></td><td><p>0.4</p></td></tr><tr><td><p>Pruritus</p></td><td><p>9.8</p></td><td><p>11.8</p></td><td><p>0.2</p></td><td><p>0.2</p></td></tr><tr><td><p>Sweating increased</p></td><td><p>5.8</p></td><td><p>14.8</p></td><td><p>0.2</p></td><td><p>0.4</p></td></tr><tr><td><p>Alopecia</p></td><td><p>4.9</p></td><td><p>22.3</p></td><td><p>0</p></td><td><p>0.6</p></td></tr><tr><td><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hemorrhage</p></td><td><p>28.9</p></td><td><p>21.2</p></td><td><p>1.8</p></td><td><p>1.7</p></td></tr><tr><td><p>GI hemorrhages</p></td><td><p>1.6</p></td><td><p>1.1</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>CNS hemorrhages</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0</p></td><td><p>0.4</p></td></tr></tbody></table><p>(1) All &nbsp;adverse &nbsp;events &nbsp;occurring &nbsp;in &nbsp;&ge;10% &nbsp;of &nbsp;patients &nbsp;are &nbsp;listed &nbsp;regardless &nbsp;of &nbsp;suspected &nbsp;relationship to treatment.</p><p>&nbsp;</p><p><strong>Table 2: Adverse Experiences Regardless of Relationship to Study Drug Reported in Other CML&nbsp;Clinical Trials (&ge;10%&nbsp;of&nbsp;all&nbsp;patients&nbsp;in any trial)(1)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p><p>&nbsp;</p><p><strong>System</strong><strong> </strong><strong>Affected</strong></p></td><td colspan="2"><p><strong>Myeloid</strong><strong> </strong><strong>blast</strong><strong> </strong><strong>crisis</strong><strong> </strong></p><p><strong>n= 260</strong></p><p><strong>(%)</strong></p></td><td colspan="2"><p><strong>Accelerated</strong><strong> </strong><strong>phase</strong><strong> </strong></p><p><strong>n=235</strong></p><p><strong>(%)</strong></p></td><td colspan="2"><p><strong>Chronic</strong><strong> </strong><strong>phase</strong><strong> IFN</strong><strong> </strong><strong>failure</strong><strong> </strong></p><p><strong>n=532</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>CTC</strong></p><p><strong>Grades</strong><strong> </strong></p><p><strong>3/4</strong></p></td><td><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>CTC</strong></p><p><strong>Grades<strong> </strong></strong></p><p><strong>3/4</strong></p></td><td><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>CTC</strong></p><p><strong>Grades</strong><strong> </strong></p><p><strong>3/4</strong></p></td></tr><tr><td><p><strong>G</strong><strong>astrointestinaldisorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>71</p></td><td><p>5</p></td><td><p>73</p></td><td><p>5</p></td><td><p>63</p></td><td><p>3</p></td></tr><tr><td><p>Vomiting</p></td><td><p>54</p></td><td><p>4</p></td><td><p>58</p></td><td><p>3</p></td><td><p>36</p></td><td><p>2</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>43</p></td><td><p>4</p></td><td><p>57</p></td><td><p>5</p></td><td><p>48</p></td><td><p>3</p></td></tr><tr><td><p>Abdo minal pain*</p></td><td><p>30</p></td><td><p>6</p></td><td><p>33</p></td><td><p>4</p></td><td><p>32</p></td><td><p>1</p></td></tr><tr><td><p>Constipation</p></td><td><p>16</p></td><td><p>2</p></td><td><p>16</p></td><td><p>0.9</p></td><td><p>9</p></td><td><p>0.4</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>12</p></td><td><p>0</p></td><td><p>22</p></td><td><p>0</p></td><td><p>27</p></td><td><p>0</p></td></tr><tr><td><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> </strong><strong>and administration site conditions</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fluid retention*</p></td><td><p>72</p></td><td><p>11</p></td><td><p>76</p></td><td><p>6</p></td><td><p>69</p></td><td><p>4</p></td></tr><tr><td><p>Superficial edemas*</p></td><td><p>66</p></td><td><p>6</p></td><td><p>74</p></td><td><p>3</p></td><td><p>67</p></td><td><p>2</p></td></tr><tr><td><p>Other fluid retention events&sup2;*</p></td><td><p>22</p></td><td><p>6</p></td><td><p>15</p></td><td><p>4</p></td><td><p>7</p></td><td><p>2</p></td></tr><tr><td><p>Pyrexia</p></td><td><p>41</p></td><td><p>7</p></td><td><p>41</p></td><td><p>8</p></td><td><p>21</p></td><td><p>2</p></td></tr><tr><td><p>Fatigue</p></td><td><p>30</p></td><td><p>4</p></td><td><p>46</p></td><td><p>4</p></td><td><p>48</p></td><td><p>1</p></td></tr><tr><td><p>Asthenia</p></td><td><p>18</p></td><td><p>5</p></td><td><p>21</p></td><td><p>5</p></td><td><p>15</p></td><td><p>0.2</p></td></tr><tr><td><p>Rigors</p></td><td><p>10</p></td><td><p>0</p></td><td><p>12</p></td><td><p>0.4</p></td><td><p>10</p></td><td><p>0</p></td></tr><tr><td><p>Chest pain</p></td><td><p>7</p></td><td><p>2</p></td><td><p>10</p></td><td><p>0.4</p></td><td><p>11</p></td><td><p>0.8</p></td></tr><tr><td><p><strong>Hepatobiliary</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Liver toxicity (including liver failure)</p></td><td><p>10</p></td><td><p>5</p></td><td><p>12</p></td><td><p>6</p></td><td><p>6</p></td><td><p>3</p></td></tr><tr><td><p><strong>Infections</strong><strong> </strong><strong>and infestations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nasopharyngitis</p></td><td><p>10</p></td><td><p>0</p></td><td><p>17</p></td><td><p>0</p></td><td><p>22</p></td><td><p>0.2</p></td></tr><tr><td><p>Pneumonia NOS</p></td><td><p>13</p></td><td><p>7</p></td><td><p>10</p></td><td><p>7</p></td><td><p>4</p></td><td><p>1</p></td></tr><tr><td><p>Upper respiratorytract infection NOS</p></td><td><p>3</p></td><td><p>0</p></td><td><p>12</p></td><td><p>0.4</p></td><td><p>19</p></td><td><p>0</p></td></tr><tr><td><p>Sinusitis NOS</p></td><td><p>4</p></td><td><p>0.4</p></td><td><p>11</p></td><td><p>0.4</p></td><td><p>9</p></td><td><p>0.4</p></td></tr><tr><td><p>Influenza</p></td><td><p>0.8</p></td><td><p>0.4</p></td><td><p>6</p></td><td><p>0</p></td><td><p>11</p></td><td><p>0.2</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Weight increase</p></td><td><p>5</p></td><td><p>1</p></td><td><p>17</p></td><td><p>5</p></td><td><p>32</p></td><td><p>7</p></td></tr><tr><td><p><strong>Metabolic</strong><strong> </strong><strong>and nutritional disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anorexia</p></td><td><p>14</p></td><td><p>2</p></td><td><p>17</p></td><td><p>2</p></td><td><p>7</p></td><td><p>0</p></td></tr><tr><td><p>Hypokalemia</p></td><td><p>13</p></td><td><p>4</p></td><td><p>9</p></td><td><p>2</p></td><td><p>6</p></td><td><p>0.8</p></td></tr><tr><td><p><strong>Musculoskeletal</strong><strong> </strong><strong>&amp;connective</strong><strong> </strong><strong>tissue</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Musculoskeletalpain*</p></td><td><p>42</p></td><td><p>9</p></td><td><p>49</p></td><td><p>9</p></td><td><p>38</p></td><td><p>2</p></td></tr><tr><td><p>Muscle cramps*</p></td><td><p>28</p></td><td><p>1</p></td><td><p>47</p></td><td><p>0.4</p></td><td><p>62</p></td><td><p>2</p></td></tr><tr><td><p>Joint pain (Arthralgia)*</p></td><td><p>25</p></td><td><p>5</p></td><td><p>34</p></td><td><p>6</p></td><td><p>40</p></td><td><p>1</p></td></tr><tr><td><p>Myalgia</p></td><td><p>9</p></td><td><p>0</p></td><td><p>24</p></td><td><p>2</p></td><td><p>27</p></td><td><p>0.2</p></td></tr><tr><td><p><strong>Nervous</strong><strong> </strong><strong>system disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Headache</p></td><td><p>27</p></td><td><p>5</p></td><td><p>32</p></td><td><p>2</p></td><td><p>36</p></td><td><p>0.6</p></td></tr><tr><td><p>Dizziness</p></td><td><p>12</p></td><td><p>0.4</p></td><td><p>13</p></td><td><p>0</p></td><td><p>16</p></td><td><p>0.2</p></td></tr><tr><td><p><strong>P</strong><strong>s</strong><strong>ychiatricdisorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Insomnia</p></td><td><p>10</p></td><td><p>0</p></td><td><p>14</p></td><td><p>0</p></td><td><p>14</p></td><td><p>0.2</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>System<strong> </strong>Affected</strong></p></td><td colspan="2"><p><strong>Myeloid</strong><strong> </strong><strong>blast</strong><strong> </strong><strong>crisis</strong><strong> </strong><strong>n= 260</strong></p><p><strong>(%)</strong></p></td><td colspan="2"><p><strong>Accelerated</strong><strong> </strong><strong>phase</strong><strong> </strong><strong>n=235</strong></p><p><strong>(%)</strong></p></td><td colspan="2"><p><strong>Chronic</strong><strong> </strong><strong>phase</strong><strong> IFN</strong><strong> </strong><strong>failure</strong><strong> </strong><strong>n=532</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>CTC</strong></p><p><strong>Grades</strong><strong> </strong></p><p><strong>3/4</strong></p></td><td><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>CTC</strong></p><p><strong>Grades</strong><strong> </strong></p><p><strong>3/4</strong></p></td><td><p><strong>All</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>CTC</strong></p><p><strong>Grades</strong><strong> </strong></p><p><strong>3/4</strong></p></td></tr><tr><td><p>Anxiety</p></td><td><p>8</p></td><td><p>0.8</p></td><td><p>12</p></td><td><p>0</p></td><td><p>8</p></td><td><p>0.4</p></td></tr><tr><td><p><strong>Respiratory</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dyspnea NOS</p></td><td><p>15</p></td><td><p>4</p></td><td><p>21</p></td><td><p>7</p></td><td><p>12</p></td><td><p>0.9</p></td></tr><tr><td><p>Cough</p></td><td><p>14</p></td><td><p>0.8</p></td><td><p>27</p></td><td><p>0.9</p></td><td><p>20</p></td><td><p>0</p></td></tr><tr><td><p>Pharyngitis</p></td><td><p>10</p></td><td><p>0</p></td><td><p>12</p></td><td><p>0</p></td><td><p>15</p></td><td><p>0</p></td></tr><tr><td><p><strong>Skin</strong><strong> </strong><strong>and subcutaneous disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash and related terms*</p></td><td><p>36</p></td><td><p>5</p></td><td><p>47</p></td><td><p>5</p></td><td><p>47</p></td><td><p>3</p></td></tr><tr><td><p>Night sweats</p></td><td><p>13</p></td><td><p>0.8</p></td><td><p>17</p></td><td><p>1</p></td><td><p>14</p></td><td><p>0.2</p></td></tr><tr><td><p>Pruritis</p></td><td><p>8</p></td><td><p>1</p></td><td><p>14</p></td><td><p>0.9</p></td><td><p>14</p></td><td><p>0.8</p></td></tr><tr><td><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hemorrhages*</p></td><td><p>53</p></td><td><p>19</p></td><td><p>49</p></td><td><p>11</p></td><td><p>30</p></td><td><p>2</p></td></tr><tr><td><p>CNS hemorrhages*</p></td><td><p>9</p></td><td><p>7</p></td><td><p>3</p></td><td><p>3</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>GI hemorrhages*</p></td><td><p>8</p></td><td><p>4</p></td><td><p>6</p></td><td><p>5</p></td><td><p>2</p></td><td><p>0.4</p></td></tr></tbody></table><p><strong>*Grouped Events</strong></p><p>(1) All&nbsp;adverse events occurring &nbsp;in &nbsp;&ge;10% of patients are listed regardless of suspected&nbsp;relationship to treatment.</p><p>(2) Other fluid retention events include pleural effusion, ascites, pulmonary edema, pericardial effusion, anasarca, edema aggravated, and fluid retention not otherwise specified.</p><p>&nbsp;</p><p><strong>Adverse Reactions in the Pediatric Population</strong></p><p>The overall safety profile of imatinib mesylate treatment in 93 pediatric patients was similar to that observed in studies with adult patients. Nausea, vomiting were the most commonly reported individual adverse events with an incidence similar to that seen in adult patients. Although most patients experienced adverse events at some time during the studies, the incidence of Grade 3 / 4 adverse events was low.</p><p>Significantly higher frequencies of hypocalcemia (23.5 vs 1.1%), hyperglycemia (19.6 vs 2.9%), hypoglycemia (21.6 vs 1.5%), hypophosphatemia (19.6 vs 3.3%), hypoalbuminemia (13.7 vs 0.2%) and hyponatremia (13.7 vs 0.2%) were observed in pediatric patients compared to adult patients.</p><p>&nbsp;</p><p><strong><u>Acute Lymphoblastic Leukemia:</u></strong></p><p>The adverse reactions were similar for Ph+ ALL as for CML. The most frequently reported non- hematologic drug- related adverse events were fluid retention (superficial edema and other fluid retention events), nausea, vomiting, diarrhea, muscle cramps, fatigue and rash. Superficial edemas were a common finding in all studies described primarily as periorbital edemas or lower limb edemas. However, these edemas were rarely severe and may be managed with diuretics, other supportive measures, or by reducing the dose of imatinib mesylate (See DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong><u>Myelodysplastic/Myeloproliferative Diseases:</u></strong></p><p>Adverse events, regardless of relationship to study drug, that were reported in at least 10% of the patients treated with imatinib mesylate for MDS/MPD in Trial B2225, are shown in Table 3.</p><p>&nbsp;</p><p><strong>Table 3 Adverse Experiences Regardless of Relationship to Study Drug Reported (more than one patient) in MDS/MPD Patients in Trial B2225 (&ge;10% all patients) all Grades</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Preferred</strong><strong> </strong><strong>term</strong></p></td><td><p><strong>N=7</strong><strong> </strong></p><p><strong>n (%)</strong></p></td></tr><tr><td><p>Nausea</p></td><td><p>4 (57.1)</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>3 (42.9)</p></td></tr><tr><td><p>Anemia</p></td><td><p>2 (28.6)</p></td></tr><tr><td><p>Fatigue</p></td><td><p>2 (28.6)</p></td></tr><tr><td><p>Muscle cramp</p></td><td><p>3 (42.9)</p></td></tr><tr><td><p>Arthralgia</p></td><td><p>2 (28.6)</p></td></tr><tr><td><p>Periorbital edema</p></td><td><p>2 (28.6)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Aggressive</strong><strong> </strong><strong>sub-types</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Systemic</strong><strong> </strong><strong>Mastocytosis</strong><strong> </strong><strong>(ASM</strong><strong> </strong><strong>and SM-AHNMD)</strong></p><p>All ASM patients experienced at least one adverse event at some time. The most frequently reported adverse events were diarrhea, nausea, ascites, muscle cramps, dyspnea, fatigue, peripheral edema, anemia, pruritis, rash and lower respiratory tract infection. None of the 5 patients in Study B2225 with ASM discontinued imatinib mesylate due to drug-related adverse events or abnormal laboratory values.</p><p>&nbsp;</p><p><strong>Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia</strong></p><p>The overall safety profile in this HES/CEL small patient population does not seem different from the known safety profile of imatinib mesylate observed in other larger populations of hematologic malignancies, such as CML. However, in patients with HES and cardiac involvement, isolated cases of cardiogenic shock/left ventricular dysfunction have been associated with the initiation of imatinib mesylate therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding imatinib mesylate (see WARNINGS and PRECAUTIONS). All patients experienced at least one adverse event, the most common being gastrointestinal, cutaneous and musculoskeletal disorders. Hematologic abnormalities were also frequent, with instances of CTC Grade 3 leukopenia, neutropenia, lymphopenia and anemia.</p><p>&nbsp;</p><p><strong>Dermatofibrosarcoma Protuberans</strong></p><p>Adverse events, regardless of relationship to study drug, that were reported in at least 10% of the 12 patients treated with imatinib mesylate for DFSP in Trial B2225 are shown in Table 4.</p><p>&nbsp;</p><p><strong>Table 4 Adverse Experiences Regardless of Relationship to Study Drug Reported in DFSP Patients in Trial B2225 (&ge;10% all patients) all Grades</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:209px"><tbody><tr><td style="width:147px"><p><strong>Preferred</strong><strong> </strong><strong>term</strong></p></td><td style="width:61px"><p><strong>N=12</strong><strong> </strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="width:147px"><p>Nausea</p></td><td style="width:61px"><p>5 (41.7)</p></td></tr><tr><td style="width:147px"><p>Diarrhea</p></td><td style="width:61px"><p>3 (25.0)</p></td></tr><tr><td style="width:147px"><p>Vomiting</p></td><td style="width:61px"><p>3 (25.0)</p></td></tr><tr><td style="width:147px"><p>Periorbital edema</p></td><td style="width:61px"><p>4 (33.3)</p></td></tr><tr><td style="width:147px"><p>Face edema</p></td><td style="width:61px"><p>2 (16.7)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Rash</p></td><td><p>3 (25.0)</p></td></tr><tr><td><p>Fatigue</p></td><td><p>5 (41.7)</p></td></tr><tr><td><p>Edema peripheral</p></td><td><p>4 (33.3)</p></td></tr><tr><td><p>Pyrexia</p></td><td><p>2 (16.7)</p></td></tr><tr><td><p>Eye edema</p></td><td><p>4 (33.3)</p></td></tr><tr><td><p>Lacrimation increased</p></td><td><p>3 (25.0)</p></td></tr><tr><td><p>Dyspnea exertional</p></td><td><p>2 (16.7)</p></td></tr><tr><td><p>Anaemia</p></td><td><p>3 (25.0)</p></td></tr><tr><td><p>Rhinitis</p></td><td><p>2 (16.7)</p></td></tr><tr><td><p>Anorexia</p></td><td><p>2 (16.7)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Reactions</u></strong><strong><u> </u></strong><strong><u>in clinical studies for CML</u></strong></p><p>The following adverse reactions as applicable are ranked under headings of frequency, the most frequent first, using the following convention: Very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1000); very rare (&lt;1/10,000), including isolated reports. Adverse reactions reported below are based on the registration studies for CML. Frequencies are determined by reported related events according to the investigator.</p><p>&nbsp;</p><p><strong>Cardiovascular</strong></p><p>&nbsp;</p><p><em>Common:&nbsp;</em></p><p>Flushing&sup1;</p><p>&nbsp;</p><p><em>Uncommon:&nbsp;</em></p><p>Palpitations, cardiac failure congestive (on a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML), pulmonary edema, tachycardia, hypertension&sup1;, hematoma&sup1;, hypotension&sup1;, peripheral coldness&sup1;, Raynaud&rsquo;s phenomenon&sup1;</p><p>&nbsp;</p><p><em>Rare:&nbsp;</em></p><p>Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Clinical</strong><strong> </strong><strong>laboratory</strong><strong> </strong><strong>Tests</strong><strong> </strong>(See Tables 5, 6 and 8)</p><p><em>Uncommon: </em></p><p>Blood CPK increased, blood LDH increased</p><p>&nbsp;</p><p><em>Rare:&nbsp; </em></p><p>Blood amylase increased</p><p>&nbsp;</p><p><strong>Dermatologic</strong></p><p><em>Common:</em></p><p>Pruritus, face edema, dry skin, erythema, alopecia, photosensitivity reaction</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Rash pustular, sweating increased, urticaria, increased tendency to bruise, exfoliative dermatitis, onychoclasis, folliculitis, petechie, psoriasis, bullous eruption, nail disorder, skin pigmentation changes, purpura, palmar-plantar erythrodysaesthesia &nbsp;syndrome</p><p>&nbsp;</p><p><em>Rare:</em></p><p>Nail discolouration, vesicular rash, erythema multiforme, leucocytoclastic vasculitis, Stevens- Johnson syndrome, acute generalized exanthematous pustulosis (AGEP), acute febrile neutrophilic dermatosis (Sweet&rsquo;s syndrome)</p><p>&nbsp;</p><p><strong>Digestive</strong></p><p><em>Common:</em></p><p>Flatulence, abdominal distension, gastroesophageal reflux, dry mouth, gastritis</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Stomatitis, mouth ulceration, eructation, malaena, oesophagitis, ascites, gastric ulcer, hematemesis, cheilitis, dysphagia, pancreatitis</p><p>&nbsp;</p><p><em>Rare:</em></p><p>Colitis, ileus, inflammatory bowel disease</p><p>&nbsp;</p><p><strong>General Disorders and Administration Site Conditions</strong></p><p><em>Common:</em></p><p>Weakness, anasarca, chills, rigors</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Chest pain, malaise</p><p>&nbsp;</p><p><strong>Hematologic</strong><strong> </strong>(See tables 6 and 7)</p><p><em>Common:</em></p><p>Pancytopenia, febrile neutropenia</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Thrombocythemia, lymphopenia, eosinophilia, lymphadenopathy</p><p>&nbsp;</p><p><em>Rare:</em></p><p>Aplastic anemia, hemolytic anemia</p><p>&nbsp;</p><p><strong>Hepatobiliary disorders</strong></p><p><em>Uncommon:&nbsp;&nbsp;&nbsp; </em></p><p>Jaundice, hepatitis, hyperbilirubinemia</p><p>&nbsp;</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Hepatic failure, hepatic necrosis (some fatal cases of hepatic necrosis have been reported)</p><p>&nbsp;</p><p><strong>Hypersensitivity</strong></p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Angioedema</p><p>&nbsp;</p><p><strong>Infections</strong></p><p><em>Uncommon:&nbsp;&nbsp;&nbsp; </em></p><p>Sepsis, herpes simplex, herpes zoster, sinusitis, cellulitis, influenza, urinary tract infection, gastroenteritis</p><p>&nbsp;</p><p><em>Rare:</em></p><p>Fungal infection</p><p>&nbsp;</p><p><em>Not known:&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Hepatitis B reactivation</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Metabolic and nutritional</strong></p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Anorexia, weight decreased</p><p>&nbsp;</p><p><em>Uncommon:&nbsp;&nbsp;&nbsp; </em></p><p>Hypophosphatemia, dehydration, gout, appetite disturbances, hyperuricemia, hypercalcemia, hyperglycemia, hyponatremia</p><p>&nbsp;</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Hyperkalemia, hypomagnesemia</p><p>&nbsp;</p><p><strong>Musculoskeletal</strong></p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em></p><p><em>J</em>oint swelling</p><p>&nbsp;</p><p><em>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em></p><p>Joint and muscle stiffness</p><p>&nbsp;</p><p><em>Rare:</em></p><p>Muscular weakness, arthritis</p><p>&nbsp;</p><p><strong>Nervous system/psychiatric</strong></p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Paresthesia, taste disturbance, hypoesthesia</p><p>&nbsp;</p><p><em>Uncommon:&nbsp;&nbsp;&nbsp; </em></p><p>Depression&sup2;, libido decrease, syncope, peripheral neuropathy, somnolence, migraine, memory impairment, sciatica, restless leg syndrome, tremor</p><p>&nbsp;</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Increased intracranial pressure, confusion, convulsions, optic neuritis</p><p>&nbsp;</p><p><strong>Neoplasm benign, malignant and unspecified (including cysts and polyps)</strong></p><p><em>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Tumor lysis syndrome</p><p>&nbsp;</p><p><strong>Renal</strong></p><p><em>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Renal pain, renal failure acute, urinary frequency increased, hematuria</p><p>&nbsp;</p><p><strong>Reproductive</strong></p><p><em>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Erectile dysfunction, breast enlargement, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, scrotal edema</p><p>&nbsp;</p><p><strong>Respiratory</strong></p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Dyspnea, epistaxis, cough</p><p>&nbsp;</p><p><em>Uncommon:&nbsp;&nbsp;&nbsp; </em></p><p>Pleural effusion (pleural effusion was reported more commonly in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML), pharyngolaryngeal pain, pharyngitis</p><p>&nbsp;</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary hemorrhage</p><p>&nbsp;</p><p><strong>Special senses</strong></p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Eyelid edema, lacrimation increased, conjunctival hemorrhage, conjunctivitis, dryeye, vision blurred</p><p>&nbsp;</p><p><em>Uncommon:&nbsp;&nbsp;&nbsp; </em></p><p>Eye irritation, eye pain, orbital edema, scleral hemorrhage, retinal hemorrhage, blepharitis, macular edema, vertigo, tinnitus, hearing loss</p><p>&nbsp;</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Cataract, papilledema, glaucoma</p><p>&nbsp;</p><p>&sup1;Vascular disorders (hematoma was most common in patients with transformed CML (CML-AP and CML-BC).</p><p>&sup2;Depression may lead to suicide ideation and/or suicide attempts.</p><p>&nbsp;</p><p><strong><u>Second malignancies in imatinib mesylate -treated patients:</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Table</strong><strong> </strong><strong>5: Observed and expected numbers of cases of second malignancies (excluding non- melanoma skin cancer) in clinical trials</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Cancer type</p></td><td rowspan="2"><p>Person-years</p></td><td colspan="2"><p>Number of cases</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td rowspan="2"><p>SIR</p><p>(95% CI)</p></td></tr><tr><td><p>Observed</p></td><td><p>Expected (1)</p></td></tr><tr><td><p>Cancer any type</p></td><td><p>10,967.03</p></td><td><p>79</p></td><td><p>91.16</p></td><td><p>0.87 (0.69-1.08)</p></td></tr><tr><td><p>Prostate</p></td><td><p>6,106.54</p></td><td><p>16</p></td><td><p>18.70</p></td><td><p>0.86 (0.49-1.39)</p></td></tr><tr><td><p>Kidney</p></td><td><p>10,769.60</p></td><td><p>3</p></td><td><p>2.26</p></td><td><p>1.33 (0.27-3.88)</p></td></tr><tr><td><p>Urinary bladder</p></td><td><p>10,766.46</p></td><td><p>2</p></td><td><p>3.72</p></td><td><p>0.54(0.06-1.94)</p></td></tr></tbody></table><p>(1) Expected in the general population</p><p>SIR: Standardized incidence ratio</p><p>&nbsp;</p><p>The numbers of cancers reported in the clinical trials were similar to those expected in the general population. The observed numbers of cases for all cancers, prostate cancer and urinary bladder cancer were slightly lower than those expected in the general population, while the number of observed kidney cancer cases was slightly higher (3 compared to 2.26 expected cases respectively). In all cases, the differences were not statistically significant.</p><p>&nbsp;</p><p><strong><u>Abnormal Hematologic and Clinical Chemistry Findings</u></strong></p><p><strong>Laboratory</strong><strong> </strong><strong>test</strong><strong> </strong><strong>abnormalities</strong><strong> </strong><strong>in CML clinical trials</strong></p><p>Cytopenias, and particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at doses &ge; 750 mg (phase I study). However, the occurrence of cytopenias was also clearly dependent on the stage of the disease.</p><p>In patients with newly diagnosed CML, cytopenias were less frequent than in other CML patients (Tables 6 and 7).</p><p>The frequency of Grade 3 or 4 neutropenia (ANC &lt;1.0x109/L) and thrombocytopenia (platelet count &lt;50x109/L) were higher in blast crisis and accelerated phase (36-48% and 32-33% for neutropenia and thrombocytopenia, respectively, Table 7) as compared to chronic phase CML (27% neutropenia and 21% thrombocytopenia). In chronic phase CML a Grade 4 neutropenia (ANC &lt;0.5x109/L) and thrombocytopenia (platelet count &lt;10x109/L) were observed in 9% and &lt;1% of patients, respectively. The median duration of the neutropenic and thrombocytopenic episodes ranged usually from 2 to 3 weeks, and from 3 to 4 weeks, respectively. These events can usually be managed with either a reduction of the dose or an interruption of treatment with imatinib mesylate, but can, in &nbsp;rare cases, lead to permanent discontinuation of treatment. (see WARNINGS and PRECAUTIONS for Hematologic Toxicity).</p><p>&nbsp;</p><p>Severe elevation of transaminases or bilirubin has been seen in &lt;5% CML patients and were usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week). Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1.0% of CML patients. There have been cases of hepatic necrosis and cholestatic hepatitis and hepatic failure; in some of which outcome was fatal (See DRUG INTERACTIONS).</p><p>&nbsp;</p><p><strong>Table 6: Newly occurring Grades 3/4 biochemical toxicities in newly diagnosed CML patients</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Parameter</strong></p></td><td colspan="2"><p><strong>Imatinib</strong><strong> </strong><strong>mesylate</strong><strong> </strong><strong>n=551</strong></p><p><strong>%</strong></p></td><td colspan="2"><p><strong>IFN+Ara-C</strong><strong> </strong></p><p><strong>n=533</strong></p><p><strong>%</strong></p></td></tr><tr><td><p><strong>Grade</strong><strong> </strong><strong>3</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>4</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>3</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>4</strong></p></td></tr><tr><td><p><strong>Hematologic</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Leucopenia</p></td><td><p>9.3</p></td><td><p>0.5</p></td><td><p>12.9</p></td><td><p>0.8</p></td></tr><tr><td><p>Neutropenia*</p></td><td><p>13.1</p></td><td><p>3.6</p></td><td><p>20.8</p></td><td><p>4.5</p></td></tr><tr><td><p>Thrombocytopenia*</p></td><td><p>8.5</p></td><td><p>0.4</p></td><td><p>15.9</p></td><td><p>0.6</p></td></tr><tr><td><p>Anemia</p></td><td><p>3.3</p></td><td><p>1.1</p></td><td><p>4.1</p></td><td><p>0.2</p></td></tr><tr><td><p><strong>Biochemistry</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Elevated creatinine</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0.4</p></td><td><p>0</p></td></tr><tr><td><p>Elevated bilirubin</p></td><td><p>0.9</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0</p></td></tr><tr><td><p>Elevated alkaline phosphatase</p></td><td><p>0.2</p></td><td><p>0</p></td><td><p>0.8</p></td><td><p>0</p></td></tr><tr><td><p>Elevated SGOT (AST)/ SGPT (ALT)</p></td><td><p>4.7</p></td><td><p>0.5</p></td><td><p>7.1</p></td><td><p>0.4</p></td></tr></tbody></table><p>* p&lt;0.001 (Difference in Grade 3 + Grade 4 abnormalities between the two treatment groups).</p><p>&nbsp;</p><p><strong>Table 7: Laboratory test abnormalities in other CML clinical trials</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Myeloid</strong><strong> </strong><strong>blast</strong><strong> </strong><strong>crisis</strong></p><p><strong>n= 260 (%)</strong></p></td><td colspan="2"><p><strong>Accelerated</strong><strong> </strong><strong>phase</strong></p><p><strong>n=235<strong> </strong>(%)</strong></p></td><td colspan="2"><p><strong>Chronic</strong><strong> </strong><strong>phase,</strong><strong> </strong><strong>IFN</strong><strong> </strong><strong>failure</strong><strong> </strong></p><p><strong>n=532</strong><strong> </strong><strong>(%)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Grade</strong><strong> </strong><strong>3</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>4</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>3</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>4</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>3</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>4</strong></p></td></tr><tr><td><p><strong>Hematology parameters</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Neutropenia</p></td><td><p>16</p></td><td><p>48</p></td><td><p>23</p></td><td><p>36</p></td><td><p>27</p></td><td><p>9</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td><p>30</p></td><td><p>33</p></td><td><p>32</p></td><td><p>13</p></td><td><p>21</p></td><td><p>&lt;1</p></td></tr><tr><td><p>Anemia</p></td><td><p>42</p></td><td><p>11</p></td><td><p>34</p></td><td><p>7</p></td><td><p>6</p></td><td><p>1</p></td></tr><tr><td><p><strong>Biochemistry</strong><strong> </strong><strong>parameters</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Elevated creatinine</p></td><td><p>1.5</p></td><td><p>0</p></td><td><p>1.3</p></td><td><p>0</p></td><td><p>0.2</p></td><td><p>0</p></td></tr><tr><td><p>Elevated bilirubin</p></td><td><p>3.8</p></td><td><p>0</p></td><td><p>2.1</p></td><td><p>0</p></td><td><p>0.6</p></td><td><p>0</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:580px"><tbody><tr><td style="width:165px"><p>Elevated alkaline phosphatase</p></td><td style="width:62px"><p>4.6</p></td><td style="width:64px"><p>0</p></td><td style="width:61px"><p>5.5</p></td><td style="width:66px"><p>0.4</p></td><td style="width:79px"><p>0.2</p></td><td style="width:82px"><p>0</p></td></tr><tr><td style="width:165px"><p>Elevated SGOT (AST)</p></td><td style="width:62px"><p>1.9</p></td><td style="width:64px"><p>0</p></td><td style="width:61px"><p>3</p></td><td style="width:66px"><p>0</p></td><td style="width:79px"><p>2.3</p></td><td style="width:82px"><p>0</p></td></tr><tr><td style="width:165px"><p>Elevated SGPT (ALT)</p></td><td style="width:62px"><p>2.3</p></td><td style="width:64px"><p>0.4</p></td><td style="width:61px"><p>4.3</p></td><td style="width:66px"><p>0</p></td><td style="width:79px"><p>2.1</p></td><td style="width:82px"><p>0</p></td></tr></tbody></table><p>CTC grades: neutropenia (grade 3 &ge;0.5 - 1.0 x 109/L), grade 4 &lt;0.5 x 109/L), thrombocytopenia (grade 3 &ge;10 - 50 x 109/L, grade 4 &lt;10 x 109/L), anemia (hemoglobin &ge;65 - 80 g/L, grade 4 &lt;65 g/L), elevated creatinine (grade 3 &gt;3-6 x upper limit normal range (ULN), grade 4 &gt;6 x ULN), elevated bilirubin (grade 3 &gt;3-10 x ULN, grade 4 &gt;10 x ULN), elevated alkaline phosphatase (grade 3 &gt; 5-20 x ULN, grade 4 &gt;20 x ULN), elevated SGOT or SGPT (grade 3 &gt;5-20 x ULN, grade 4 &gt;20 x ULN).</p><p>Clinically relevant or severe abnormalities of the 12 patients treated with imatinib mesylate for DFSP in Trial B2225 are presented in Table 8.</p><p>&nbsp;</p><p><strong>Table 8: Laboratory Abnormalities Reported in DFSP Patients in Trial B2225&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>N=12</strong></p></td></tr><tr><td><p><strong>CTC</strong><strong> </strong><strong>Grades</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>3</strong></p></td><td><p><strong>Grade</strong><strong> </strong><strong>4</strong></p></td></tr><tr><td><p><strong>Hematologyparameters</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anemia</p></td><td><p>17%</p></td><td><p>0%</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td><p>17%</p></td><td><p>0%</p></td></tr><tr><td><p>Neutropenia</p></td><td><p>0%</p></td><td><p>8%</p></td></tr><tr><td><p><strong>Biochemistry</strong><strong> </strong><strong>parameters</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Elevated creatinine</p></td><td><p>0%</p></td><td><p>8%</p></td></tr><tr><td colspan="3"><p>CTC Grades: neutropenia (Grade 3 &ge; 0.5-1.0 x 109/L, Grade 4&lt; 0.5 x 109/L), thrombocytopenia (Grade 3 &ge; 10-50 x 109/L,&nbsp;Grade 4&lt; 10 x 109/L),&nbsp;anemia (Grade 3 &ge; 65-80 g/L, Grade 4&lt; 65 g/L), elevated creatinine (Grade 3&gt;3-6 x upper limit normal range [ULN], Grade 4 &gt;6 x ULN).</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Reactions</u></strong><strong><u> </u></strong><strong><u>from Post-Marketing Reports</u></strong></p><p>The following types of ADRs have been reported from post-marketing experience and from additional clinical studies with imatinib mesylate. They include spontaneous case reports as well as serious ADRs from smaller or ongoing clinical studies and the expanded access programs. Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to imatinib mesylate exposure.</p><p>&nbsp;</p><p><strong>Cardiovascular:</strong><strong> </strong>thrombosis/embolism&sup1;, pericarditis, cardiac tamponade, anaphylactic shock&sup1; subdural hematoma1</p><p>&nbsp;</p><p><strong>Dermatology:</strong><strong> </strong>lichenoid keratosis, lichen planus, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic syndroms (DRESS)</p><p>&nbsp;</p><p><strong>Digestive:</strong><strong> </strong>ileus/intestinal obstruction, tumor hemorrhage/tumor necrosis, gastrointestinal perforation (some fatal cases of gastrointestinal perforation have been reported) Diverticulitis</p><p>&nbsp;</p><p><strong>General:</strong><strong> </strong>motor vehicle accidents</p><p>&nbsp;</p><p><strong>Hepatic:</strong><strong> </strong>Hepatitis, Hepatotoxicity with fatal outcomes (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS)</p><p>&nbsp;</p><p><strong>Hepatitis</strong><strong> </strong><strong>B reactivation : </strong>Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome (see WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p><strong>Musculoskeletal:</strong><strong> </strong>avascular necrosis/hip osteonecrosis, rhabdomyolysis/myopathy, growth retardation in children</p><p>&nbsp;</p><p><strong>Nervous</strong><strong> </strong><strong>system/psychiatric:</strong><strong> </strong>cerebral edema (including fatalities)</p><p>&nbsp;</p><p><strong>Reproductive:</strong><strong> </strong>Hemorrhagic corpus luteum/hemorrhagic ovarian cyst</p><p>&nbsp;</p><p><strong>Respiratory:</strong><strong> </strong>acute respiratory failure (fatal cases have been reported in patients with advanced disease, severe infections, severe neutropenia and other serious concomitant conditions), interstitial lung disease</p><p>&nbsp;</p><p><strong>Special</strong><strong> </strong><strong>senses:</strong><strong> </strong>vitreous hemorrhage</p><p>&nbsp;</p><p><strong>Neoplasm</strong><strong> </strong><strong>benign,</strong><strong> </strong><strong>malignant</strong><strong> </strong><strong>and</strong><strong> </strong><strong>unspecified</strong><strong> </strong><strong>(including</strong><strong> </strong><strong>cysts and polyps): </strong>Tumor lysis syndrome, some of which were fatal.</p><p>&nbsp;</p><p>&sup1;Vascular disorders.</p><p>&nbsp;</p><p>-&nbsp; To report any side effect(s)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with higher than therapeutic doses is limited. Isolated cases of imatinib mesylate overdosage have been reported spontaneously and in the literature. Generally the reported outcome in these cases was improvement or recovery. In the event of overdosage the patient should be observed and appropriate symptomatic treatment should be given.</p><p>&nbsp;</p><p>Events that have been reported at different dose ranges are as follows:</p><p>&nbsp;</p><p><strong>Adult overdose:</strong></p><p>1,200 to 1,600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite, increased bilirubin and liver transaminase level.1,800 to 3,200 mg (as high as 3,200 mg daily for 6 days): Weakness, myalgia, increased CPK, increased bilirubin, gastrointestinal pain. 6,400 mg (single dose): A case report in the literature about one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, neutrophil count decreased, increased transaminases. 8 to 10 g (single dose): Vomiting and gastrointestinal pain have been reported.</p><p>&nbsp;</p><p><strong>Pediatric overdose:</strong></p><p>One 3 year-old male exposed to a single dose of 400 mg experienced vomiting, diarrhoea and anorexia and another 3 year old male exposed to a single dose of 980 mg dose experienced decreased white blood cell count and diarrhea.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Protein kinase inhibitor</p><p>ATC code: L01XE01</p><p>KETOVA (imatinib mesylate) is a protein tyrosine kinase inhibitor, which inhibits the Bcr-Abl tyrosine kinase at the &nbsp;in vitro, cellular, and in vivo levels. The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoid leukemia (ALL) patients. In colony formation assays using ex vivo peripheral blood and bone marrow samples, imatinib shows selective inhibition of Bcr-Abl positive colonies from CML patients.</p><p>In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as well as Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.</p><p>In addition, imatinib is an inhibitor of several receptor tyrosine kinases: the platelet-derived growth factor receptors (PDGFR-&alpha; and PDGFR-&beta;), and the stem cell factor (SCF), receptor (c- Kit), and it inhibits the cellular events mediated by these receptors.</p><p>Constitutive activation of the PDGFR or the Abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of PDGF have been implicated in the pathogenesis of several conditions including MDS/MPD, HES/CEL and DFSP. In addition, constitutive activation of c-Kit or the PDGFR has been implicated in the pathogenesis of SM. Imatinib inhibits signaling and proliferation of cells driven by dysregulated PDGFR, Kit and Abl kinase activity.</p><p>Several mechanisms of resistance have been identified from in vitro studies of Bcr-Abl positive cell lines. Mechanisms include amplification of the Bcr-Abl gene and overexpression of the multidrug resistance P- glycoprotein. Mutation or amplification of the Bcr-Abl gene has been described in relapsed patients with advanced stage CML.</p><p>Prevalence of Abl kinase domain mutations among samples of resistant CML patients varies across studies, likely reflecting variations in time frames for testing, the duration of imatinib exposure, patient selection differences, and perhaps differences in techniques and sensitivity.</p><p>The specific clinical relevance of Abl kinase domain mutations in the prognosis and management of patients with CML requires further study. It is likely that mutations will have different clinical phenotypes, with some being subject to higher-dose imatinib therapy, depending on the IC50 of the mutation, and others requiring alternative treatment strategies.</p><p>Recent in-vitro experiments have indicated that some mutations remain sensitive to imatinib mesylate at high concentrations, other mutants remain unresponsive to dose escalation, which may indicate a kinase-independent, or even Bcr-Abl independent mechanisms of resistance.</p><p>Currently identified possible mechanisms of resistance to imatinib mesylate can be categorized in two main groups: the mechanisms where Bcr-Abl is reactivated and cell proliferation remains dependent on Bcr-Abl signaling, and mechanisms where the Bcr-Abl protein remains inactivated by imatinib mesylate but alternative signalling pathways become activated. Whereas the primary resistance to imatinib mesylate seems mostly associated with amplification of the Bcr-Abl gene, secondary resistance (ie. loss of response or progression) appears to be associated with the emergence of mutations of the Bcr-Abl gene (see below):</p><p>&nbsp;</p><p><strong>Currently identified mechanisms of resistance to imatinib</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Bcr-Abl</strong><strong> </strong><strong>dependent</strong><strong> </strong><strong>mechanisms (cells<strong> </strong>remain</strong><strong> </strong><strong>dependent</strong><strong> </strong><strong>of Bcr-Abl signaling)</strong></p></td><td><p><strong>Bcr-Abl</strong><strong> </strong><strong>independent</strong><strong> </strong><strong>mechanisms&nbsp;</strong><strong>(Bcr-Abl</strong><strong> </strong><strong>is</strong><strong> </strong><strong>inactivated)</strong></p></td></tr><tr><td><p>Amplification of Bcr-Abl gene</p></td><td><p>Activation of signaling pathways downstream of Bcr-Abl</p></td></tr><tr><td><p>Mutations of Bcr-Abl preventing correct Bcr-Abl imatinib binding</p></td><td><p>Clonal evolution with appearance of new chromosomal abnormalities</p></td></tr><tr><td><p>Efflux of imatinib by PgP associated MDR protein</p></td><td><p>Activation of leukemogenic pathways unrelated to Bcr-Abl</p></td></tr><tr><td><p>Protein binding of imatinib (eg. to circulating AGP)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>P-gP: Protein&ndash;glyco-Protein</p><p>MDR: Multidrug Resistance</p><p>AGP: Alpha 1-acid glycoprotein</p><p>&nbsp;</p><p>The clinical utility of detecting mutations remains to be demonstrated, since mutations have been described among imatinib mesylate treated patients without evidence of disease progression. In addition, the approach to managing resistance will differ by CML disease stage, irrespective of treatment. Clinical and molecular resistance is much more prevalent among patients with blast crisis and accelerated phase CML, than among patients with chronic phase CML.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics (PK) of imatinib mesylate have been evaluated in 591 patients and 33 healthy subjects over a dosage range of 25 to 1000 mg.</p><p>&nbsp;</p><p><strong>Absorption:</strong><strong> </strong>Mean absolute bioavailability for the capsule formulation is 98%. The coefficient of variation for plasma imatinib AUC is in the range of 40-60% after an oral dose. When given with a high fat meal the rate of absorption of imatinib was reduced (11% decrease in Cmax and prolongation of tmax by 1.5 h), with a small reduction in AUC (7.4%) compared to fasting conditions.</p><p>&nbsp;</p><p><strong>Distribution:</strong><strong> </strong>At clinically relevant concentrations of imatinib, binding to plasma proteins is approximately 95% on the basis of in vitro experiments, mostly to albumin and &infin;1-acid glycoprotein, with little binding to lipoproteins.</p><p>In in vitro experiments, the active metabolite, CGP74588, exhibited similar protein binding behaviour to imatinib at clinically relevant concentrations.</p><p>&nbsp;</p><p><strong>Metabolism:</strong><strong> </strong>CYP3A4 is the major enzyme responsible for metabolism of imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism.</p><p>The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to the parent imatinib. The plasma AUC for this metabolite is about 15% of the AUC for imatinib and the terminal half-life is approximately 40 h at steady state. The plasma protein binding of the N-demethylated metabolite CGP74588 was shown to be similar to that of the parent compound in both healthy volunteers and Acute Myeloid Leukemia (AML) patients although there were variabilities in blood distribution and protein binding between AML patients. Some of the AML patients showed a significantly higher unbound fraction of both compounds which led to a higher blood cell uptake.</p><p>A phase I study has shown a 4- to 7-fold accumulation of the metabolite CGP74588 at steady state following once daily dosing, which was greater than the parent drug (See below: plasma pharmacokinetics). This might be due to the fact that CGP74588 is metabolized at a 53% lower metabolic conversion rate compared to imatinib mesylate in human hepatocytes. The reduced metabolic clearance of CGP74588 is further implied by in vitro experiments which showed a lower infinity of CGP74588 to CYP3A4 in comparison to STI571.</p><p>&nbsp;</p><p><strong>Excretion:</strong><strong> </strong>Based on the recovery of compound(s) after an oral 14C-labelled dose of imatinib, approximately 81% of the dose was eliminated within 7 days in feces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being metabolites.</p><p>&nbsp;</p><p><strong>Plasma</strong><strong> </strong><strong>pharmacokinetics:</strong><strong> </strong>Following oral administration in healthy volunteers, the t&frac12; was approximately 18 hours suggesting that once daily dosing is appropriate. Plasma pharmacokinetic profiles were analyzed in CML patients on Day 1 and on either Day 7 or 28, by which time plasma concentrations had reached steady state. The increase in mean imatinib AUC with increasing dose was linear and dose proportional in the range 25-1000 mg &nbsp;after oral administration. There was no change in the kinetics of imatinib on repeated dosing, and accumulation is 1.5-2.5 fold at steady state when imatinib mesylate is dosed once daily.</p><p>&nbsp;</p><p>The effect of body weight on the clearance of imatinib is such that for a patient weighing 50 kg the mean clearance is expected to be 8.5 l/h, while for a patient weighing 100 kg the clearance will rise to 11.8 l/h. These changes are not considered sufficient to warrant dose adjustment based on body weight. There is no effect of gender on the kinetics of imatinib.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions:</u></strong></p><p><strong>Pediatrics:</strong><strong> </strong>A total of 31 pediatric patients with either chronic phase CML (n=15), CML in blast crisis (n = 4) or acute leukemias (n=12) have been enrolled in a dose-escalation phase I trial. In this trial the effective dose in pediatric patients was not identified. This was a population of heavily pretreated patients; 45% had received prior BMT and 68% prior multi-agent chemotherapy. Newly diagnosed patients or those eligible for bone marrow transplantation were not studied. The median age was 14 years (range 3 to 20 years). Of the 31 patients, n=12 &nbsp;were three to 11 years old at the start of the study, n= 17 were between 12 and 18 years, and only two were more than 18 years old. Patients were treated with doses of imatinib mesylate of 260 mg/m2/day (n=6), 340 mg/m2/day (n=11), 440 mg/m2/day (n= 8) and 570 mg/m2/day (n=6). Dosing based upon body surface area resulted in some patients receiving higher than the adult therapeutic dose, and the effect of this on pediatric patient safety is limited.</p><p>&nbsp;</p><p>As in adult patients, imatinib was rapidly absorbed after oral administration in pediatric patients in both phase I and phase II studies. Dosing in children at 260 and 340 mg/m2/day achieved similar exposure, respectively, as &nbsp;doses of 400 mg and 600 mg in adult patients, although this was based upon a small sample size. The comparison of AUC0-24 on Day 8 versus Day 1 at the 340 mg/m2/day dose level revealed a 1.7- fold drug accumulation after repeated once daily dosing. As in adults, there was considerable inter-patient variability in the pharmacokinetics, and the coefficient of variation for AUC0-24 ranged from 21% (260 mg/m2/day) to 68% (570 mg/m2/day). The AUC did not increase proportionally with dose within the range of doses examined. The active metabolite, GCP 74588, contributed about 20% of the AUC for imatinib. Total plasma clearance is about 8 - 10 L/h at steady state. The plasma AUC of imatinib is significantly lower (p=0.02) in children at ages between 2 and &lt;12 years old (29.3 ug*hr/mL) than those at ages between 12 and &lt;20 years old (34.6 ug*hr/mL). However, the difference between &nbsp;the two age groups does not seem to be clinically significant, only 15% of difference (geometric mean of 29.3 in children compared to 34.6 in adolescents). The AUC exposure in both age groups falls within the adult AUC(0-24h) range, between 24.8 and 39.7 &mu;g*h/ml, achieved at 400 mg and 600 mg daily doses, respectively.</p><p>&nbsp;</p><p><strong>Geriatrics:</strong><strong> </strong>Based on population PK analysis, there was an effect of age on the volume of distribution (12% increase in patients &gt; 65 years old). This change is not thought to be clinically significant.</p><p>&nbsp;</p><p><strong>Hepatic</strong><strong> </strong><strong>Insufficiency:</strong><strong> </strong>In a study of patients with mild and moderate hepatic dysfunction (Table 10), the mean exposure to imatinib (dose normalized AUC) did not differ significantly compared with patients with normal liver function. There was a tendency toward an increased exposure in patients with severe liver dysfunction (approximately 45% increase compared with patients with normal liver function). In this study up to 500 mg daily was used in patients with mild liver dysfunction, up to 400 mg daily in patients with moderate, and up to 300 mg daily in patients with severe liver dysfunction.</p><p>In the severe liver dysfunction group 29% of patients experienced serious adverse events at the 100 mg dose level, 60% at the 200 mg and 50% of patients treated at the 300 mg dose levels. (See sections WARNINGS and PRECAUTIONS and DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Table 10: Liver Dysfunction Classification</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Liver</strong><strong> </strong><strong>Dysfunction</strong></p></td><td><p><strong>Liver</strong><strong> </strong><strong>Dysfunction</strong><strong> </strong><strong>Tests</strong></p></td></tr><tr><td><p>Mild</p></td><td><p>Total bilirubin: = 1.5 ULN</p><p>SGOT: &gt;ULN (can be normal or &lt;ULN if Total bilirubin is &gt;ULN)</p></td></tr><tr><td><p>Moderate</p></td><td><p>Total bilirubin: &gt;1.5-3.0 ULN SGOT: any</p></td></tr><tr><td><p>Severe</p></td><td><p>Total bilirubin: &gt;3-10 ULN SGOT: any</p></td></tr></tbody></table><p>ULN=upper limit of normal for the institution</p><p>SGOT= serum glutamic oxaloacetic transferase</p><p>&nbsp;</p><p><strong>Renal</strong><strong> </strong><strong>Insufficiency:</strong><strong> </strong>Imatinib and its metabolites are not excreted via the kidney to a significant extent.</p><p>In a study of patients with varying degrees of renal dysfunction (mild, moderate and severe &ndash; see Table 11 below for renal function classification), the mean exposure to imatinib (dose normalized AUC) increased 1.5- to 2-fold compared to patients with normal renal function, which corresponded to an elevated plasma level of AGP, a protein to which imatinib binds strongly. There was a correlation with the incidence of serious adverse events and decreasing renal function (p = 0.0096). In this study, 800 mg daily was used in patients with mild renal dysfunction and 600 mg daily was used in patients with moderate renal dysfunction. The 800 mg dose was not tested in patients with moderate renal dysfunction due to the limited number of patients enrolled. Similarly, only 2 patients with severe renal dysfunction were enrolled at the low (100 mg) dose, and no higher doses were tested. No patients on hemodialysis were enrolled in the study. Since the effect of imatinib mesylate treatment on patients with severe renal dysfunction and on hemodialysis has not been sufficiently assessed, treatment of these patients with imatinib cannot be recommended. Patients with mild or moderate renal dysfunction should be treated with cautio n, and be given the minimum recommended dose of 400 mg daily as starting dose. The dose should be reduced if not tolerable. If tolerated, the dose can be increased for lack of efficacy. Dosing of patients with moderate renal insufficiency at 800 mg cannot be recommended as this has not been investigated (See sections Undesirable effects; DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p><strong>Table 11: Renal function classification</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Renal</strong><strong> </strong><strong>dysfunction</strong></p></td><td><p><strong>Renal</strong><strong> </strong><strong>function</strong><strong> </strong><strong>tests</strong></p></td></tr><tr><td><p><strong>Mild</strong></p></td><td><p>CrCL = 40-59 mL/min</p></td></tr><tr><td><p><strong>Moderate</strong></p></td><td><p>CrCL = 20-39 mL/min</p></td></tr><tr><td><p><strong>Severe</strong></p></td><td><p>CrCL = &lt; 20 mL/min</p></td></tr></tbody></table><p>CrCL = Creatinine Clearance</p><p>&nbsp;</p><p><strong>Drug-Drug Interactions</strong></p><p><strong><em>CYP3A4 Inhibitors: </em></strong>There was a significant increase in exposure to imatinib (mean Cmax and AUC increased by 26% and 40%, respectively) in healthy subjects when imatinib mesylate was coadministered with a single dose of ketoconazole (a CYP3A4 inhibitor). (See DRUG INTERACTIONS).</p><p>&nbsp;</p><p><strong><em>CYP3A4 Substrates: </em></strong>Imatinib increased the mean Cmax and AUC of simvastatin (CYP3A4 substrate) by 2- and 3.5- fold, respectively, indicating an inhibition of CYP3A4 by imatinib. (See DRUG INTERACTIONS).</p><p>&nbsp;</p><p><strong><em>CYP3A4 Inducers: </em></strong>Administration of rifampin 600 mg daily for eight days to 14 healthy adult volunteers, followed by a single 400 mg dose of imatinib mesylate increased imatinib oral dose clearance by 3.8-fold (90% CI 3.5- to 4.3-fold). Mean Cmax, AUC0-24 and AUC0-&infin; decreased by 54%, 68% and 74%, respectively compared to treatment without rifampin. In patients in whom rifampin or other CYP3A4 inducers are indicated, alternate therapeutic agents with less enzyme induction potential should be considered. (See DRUG INTERACTIONS).</p><p>&nbsp;</p><p><strong><em>In</em></strong><strong><em> </em></strong><strong><em>vitro Studies of CYP Enzyme Inhibition: </em></strong>Human liver microsome studies demonstrated that imatinib is a potent competitive inhibitor of CYP2C9, CYP2D6, and CYP3A4/5 with Ki values of 27, 7.5, and 8 &mu;M, respectively. Imatinib is likely to increase the blood level of drugs that are substrates of CYP2C9, CYP2D6 and CYP3A4/5. (See DRUG INTERACTIONS).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute</strong><strong> </strong><strong>Toxicity</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Species</p></td><td><p>Route</p></td><td><p>Doses (mg/kg)</p></td><td><p>Main findings</p></td></tr><tr><td><p>Rat</p></td><td><p>i.v.</p></td><td><p>10, 30 &amp;100</p></td><td><p>1 death at 100 mg/kg attributed to lung injury, due to precipitation of the compound. Well tolerated at 10 and 30 mg/kg.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Doses higher than 100 mg/kg were not administered due to the limited solubility of imatinib at neutral pH. The compound was well tolerated at both the low and mid dose. However, there was one death at the high dose (out of ten rats treated) which occurred 30 minutes post-dose. Death was attributed to lung injury, most probably as a result of precipitation of the compound in the pulmonary microcirculation. No other treatment-related changes were noted. Based on these results, 30 mg/kg is considered to be the maximum dose of STI571 which can be administered by slow i.v. bolus injection to rats without causing symptoms.</p><p>&nbsp;</p><p><strong>Subacute and Chronic Toxicity</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Study Type</p></td><td><p>Species</p></td><td><p>Route</p></td><td><p>Doses (mg/kg)</p></td><td><p>Findings</p></td></tr><tr><td colspan="5"><p><strong>Intravenous</strong></p></td></tr><tr><td><p>2 weeks</p></td><td><p>Rat</p></td><td><p>i.v.</p></td><td><p>0.3, 3 &amp; 30</p></td><td><p>At &ge;0.3 mg/kg, decreased WBC/lymphocytes. At 30 mg/kg, slight reduction in erythrocyte parameters and thymic atrophy. Slight inflammation at injection sites at all dosages. NOAEL 3 mg/kg.</p></td></tr><tr><td><p>4 weeks</p></td><td><p>Rat</p></td><td><p>i.v.</p></td><td><p>0.1, 3 &amp; 30</p></td><td><p>No major findings; increased prostate weight without microscopic changes at &ge; 3 mg/kg.</p></td></tr><tr><td><p>rising dose</p></td><td><p>Dog</p></td><td><p>i.v.</p></td><td><p>3, 10 &amp; 30</p></td><td><p>At 30 mg/kg, decreased WBC &amp; absolute neutrophil counts, increased ALT. Clinical signs included hypoactivity and hypersensit ivityto touch.</p></td></tr><tr><td><p>4 weeks</p></td><td><p>Dog</p></td><td><p>i.v.</p></td><td><p>3, 10 &amp; 30</p></td><td><p>At 10 mg/kg, changes confined to decreased WBC &amp; neutrophil counts. At 30 mg/kg, local reaction at injection sites, ataxia, hypoactivity, skin changes, decreased erythrocyte parameters, WBC &amp; neutrophils, increased ALT, perivascular fibrosis &amp; necrosis, thrombosis and edema at the injection site, decreased testis weight without microscopic change.</p></td></tr><tr><td><p>4 weeks</p></td><td><p>Dog</p></td><td><p>i.v.</p></td><td><p>20 &amp; 60:</p><p>3 hour infusio n/day for 7 days; 24 hour infusion thereafter</p></td><td><p>Mortality at 60 mg/kg. At &ge;6 mg/kg, increased granulopoiesis decreased RBC parameters. At &ge;20 mg/kg, decreased WBC, biochemical changes in serum indicating liver toxicity, necrotizing phlebitis, thrombosis in various organs; fatty replacement of bone marrow cells. At 60 mg/kg, reduced erythropoiesis. No NOAEL.</p></td></tr><tr><td colspan="5"><p><strong>Intraperitoneal</strong></p></td></tr><tr><td><p>2-weeks</p></td><td><p>Rat</p></td><td><p>i.p.</p></td><td><p>0.3, 3 &amp; 30</p></td><td><p>At 30 mg/kg, decreased erythrocyte parameters and alkaline phosphatase levels. Inflammation of the parietal and visceral peritoneum. NOEL 3 mg/kg, with the exception of mild effects at the injection site.</p></td></tr><tr><td colspan="5"><p><strong>Oral</strong></p></td></tr><tr><td><p>2 weeks</p></td><td><p>Rat</p></td><td><p>p.o.</p></td><td><p>60, 200 &amp; 600</p></td><td><p>Death or early kill at 600 mg/kg, with general deterioration. At all doses, evidence in serum of dose-related liver effects, hemorrhagic ovaries, increased mitoses in the liver; red cell, WBC/lymphocyte counts reduced, hypocellularit yof bone marrow. At &ge; 200 mg/kg, enlarged stomachs &amp; degenerative changes, including vacuo lation, single cell necrosis or more widespread necrosis in a number of tissues, predominant lyof epithelial origin; hist iocytosis. At 600 mg/kg, hypertrophy of Kupffer cells, accumulation of macrophages in blood vessels in liver and lung, atrophic changes in thyroid, salivary, Harderian and mammary glands, prostate and seminal vesicles. Atrophy and histiocytosis in lymphoid tissues. All effects dose- related.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Study Type</p></td><td><p>Species</p></td><td><p>Route</p></td><td><p>Doses (mg/kg)</p></td><td><p>Findings</p></td></tr><tr><td><p>13 weeks</p></td><td><p>Rat</p></td><td><p>p.o.</p></td><td><p>6, 20 &amp; 60</p></td><td><p>At 60 mg/kg, evidence of liver effects in serum. At 20 and 60 mg/kg, decreases in RBC parameters &amp; decreased cellularity of bone marrow. Hyperplasia of transitional epithelium in renal papilla &amp; bladder at all dosages, minimal at 6 mg/kg. Lymphoid &amp; plasma cell hyperplasia in lymph nodes at &ge; 20 mg/kg. At 60 mg/kg, increased mitotic figures in the liver, hemorrhagic ovaries, vacuo lation of Harderian glands, increased alveolar macrophages; hemorrhage, hemosiderosis and increased hist iocytes in mesenteric lymph nodes. Effects at 6 mg/kg confined to microscopic findings in kidney/bladder.</p></td></tr><tr><td><p>13 weeks (repeated)</p></td><td><p>Rat</p></td><td><p>p.o.</p></td><td><p>0.3, 1, 3 &amp; 10</p></td><td><p>No effect at any dose level.</p></td></tr><tr><td><p>26-week</p></td><td><p>Rat</p></td><td><p>p.o.</p></td><td><p>5, 15, 50</p></td><td><p>50 mg/kg: Mortality(2m). Red ears, squinting, swollen appendages, red feet, dry perineal staining, apparent blood or dark yellow urine on cage paper, swollen muzzles and appendages, and dry staining of fur. Slight decrease in body weight (f). Decreased neutrophils, eosinophils, hematocrit, hemoglobin, platelets; increased MCV, MCH, MCHC and red cell distribution width. Increased AST, ALT, total protein, albumin, globulin; decreased A/G ratio, sodium, cholesterol and triglycerides. Increased heart (f), adrenal, liver (m), thyroid (m) and ovary weights; decreased pituitary (f) and testis weights.</p><p>Enlarged masseter muscles and dark or red ovarian nodules. Hemorrhagic and/or cystic corpora lutea, hemosiderin-laden macrophages in ovaries, foamy macrophage accumulation in lungs, focal angiectasis of adrenal cortex, hypertrophy of masseter muscles, focal</p><p>mineralizat ion/hyperplasia of renal pelvic epithelium and focal new bone formation.</p><p>&ge; 15 mg/kg: Prominent eyes, wet perineal staining, increased incidence/frequency of chro modacryorrhea and red penile discharge. Decreased RBC counts and platelets. Increased heart (m) and spleen weights. Focal fibrosis of bone marrow, atrophy of acinar cells of harderian gland, increased eosinophilic macrophages in mesenteric lymph nodes.</p><p>&ge;&nbsp;&nbsp; 5&nbsp; &nbsp;mg/kg: &nbsp;Salivation,&nbsp;&nbsp; presence &nbsp;of &nbsp;oral &nbsp;red&nbsp; &nbsp;substance,&nbsp; &nbsp;chro modacryorrhea, &nbsp;increased incidence/frequencyof chromorhinorrhea.</p><p>Most changes were reversible or partially reversible by the end of the recoveryperiod. NTEL = 5 mg/kg.</p></td></tr><tr><td><p>2-week</p></td><td><p>Dog</p></td><td><p>p.o.</p></td><td><p>10, 30 &amp; 100</p></td><td><p>No deaths. Occasional emesis and diarrhea at 100 mg/kg. Evidence in serum of liver changes, and decreased leucocyte counts &amp; RBC parameters at 30 &amp; 100 mg/kg. At 100 mg/kg, liver weight increased &amp; centrilobular/ midzonal hepatocyte hypertrophy with increased mitosis and apoptosis, vacuolar degeneration hyperplasia/hypertrophyof epithelium of intrahepatic bile ducts and gall bladder. Vacuolar degeneration of gastric mucosa and renal pelvis. Fibrin thrombi in capillaries of small intestine villi with vasculitis and edema. Decreased thymus weight, lymphocytolysis in lymphoid organs, and bone marrow hypocellularity (dose related) at &ge; 30 mg/kg. NOEL 10 mg/kg.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Study Type</p></td><td><p>Species</p></td><td><p>Route</p></td><td><p>Doses (mg/kg)</p></td><td><p>Findings</p></td></tr><tr><td><p>13 weeks</p></td><td><p>Dog</p></td><td><p>p.o.</p></td><td><p>3, 10, 30 &amp; 100</p><p>reduced to 50</p></td><td><p>Death in 1 male at 100 reduced to 50 mg/kg. At &ge; 10 mg/kg, dose-related diarrhea; decreases in RBC counts, and bone marrow hypo-cellularity in some animals; increased ovary weights, hepatic inflammation; gastric &amp; small intestinal changes; thyroid weights decreased with follicular atrophy; increased splenic hemopoiesis. At &gt;30 mg/kg dose-related emesis; decreased WBC, liver toxicity markers in serum; bile duct hyperplasia; pigment deposition in various tissues; thymic atrophy; focal acinar atrophy in the pancreas; reduced spermatogenesis. At high dose decreased testis weight, vacuo lat ion of hepatocytes &amp; bile duct epithelium; cystic corpora lutea containing hemorrhagic fluid; after recovery period peri-biliary fibrosis also present. NOEL = 3 mg/kg.</p></td></tr><tr><td><p>4 weeks (exploratory)</p></td><td><p>Dog</p></td><td><p>p.o.</p></td><td><p>100</p></td><td><p>Moribundity(1m). Salivation and vomiting, resistance to dosing, headshaking, diarrhea, hypoactivit y, grey discoloration of fur. Moderate to marked decreased food consumption and body weight loss (reversible). Slight to moderate anemia (decreased reticulocytes and moderately decreased WBC due to decreased neutrophils). Liver alterations: degenerative lesions in biliary system(reversible) and hepatocytes (non-reversible), inflammatorycell infiltration, pigment deposition (mainly Kupffer cells) and bile duct hyperplasia, peribiliary fibrosis and increased perivascular infiltration of granulocytes and precursor cells. Electron microscopy: myelo id bodies in hepatocytes and Kupffer cells. Immunohistochemical analysis: antibodies reacting with nucleoli of hepatocytes and presence of bile duct epithelial cells.</p></td></tr><tr><td><p>2 weeks</p></td><td><p>Monkey</p></td><td><p>p.o.</p></td><td><p>10, 30,100 &amp; 300</p><p>reduced to 200</p></td><td><p>Single doses of 200 and 300 mg/kg not tolerated. At 100 mg/kg emesis, decreased body weight, slight decrease in hematocrit,centrilobular&nbsp; vacuolation of the liver. NOEL = 30 mg/kg</p></td></tr><tr><td><p>13 weeks</p></td><td><p>Monkey</p></td><td><p>p.o.</p></td><td><p>3, 15 &amp; 75</p></td><td><p>Reduced erythrocyte parameters, emesis, pale gums and skin at 75 mg/kg/day. One female at 15 mg/kg/day also showed pale gums and skin. No test-article-related macroscopic or microscopic changes. NTEL = 15 mg/kg/day.</p></td></tr><tr><td><p>2-week b.i.d.</p></td><td><p>Monkey</p></td><td><p>p.o.</p></td><td><p>20, 75 &amp;</p><p>150&rarr;100</p></td><td><p>Twice daily dosing. Unscheduled sacrifice 150&rarr;100 due to poor general condition. Clinical signs at doses &ge;75mg/kg: diarrhea, fecal changes, pale gums, and emesis with or without feed. At 150&rarr;100 increased creatinine, BUN, total bilirubin and decreased chloride and sodium; focal mineralization and dilatation of kidneytubules; tubular nephrosis; vacuolization of centrilobular hepatocytes; thymic atrophy.</p><p>Toxicokinetics: No apparent gender difference in exposure, proportional increase in plasma concentrations seen with increasing dose. AUC(0-18): 1160, 40700 and 34550 ng.h/ml (m), 3270, 9430 and 41250 ng.h/mL (f).</p></td></tr><tr><td><p>39-week b.i.d.</p></td><td><p>Monkey</p></td><td><p>p.o.</p></td><td><p>15, 30, 80</p></td><td><p>Results at 6 months: Twice daily dosing 80 mg/kg: Reduced feces, diarrhea (m, f), and reddened conjunctiva/eyelid, pale gingiva (m). Decreased food consumption and body weight change (f).</p><p>&ge; 30 mg/kg: Decreased food consumption and body weight change (m). Reduced albumin. Decreased RBC count, hemoglobin and hematocrit, increased MCV, MCH and MCHC. Presence of Plasmodium species (malaria).</p><p>&ge; 15 mg/kg: Soft feces.</p></td></tr></tbody></table><p>The toxicity after i.v. bolus administration was qualitatively similar to that seen after oral dosing. Irritation at the injection site was seen after peripheral i.v. administration in most studies using this route of administration.</p><p>Mild to moderate hematological changes were observed in rats, dogs and monkeys at oral doses &ge; 20, 10 and 75 mg/kg, respectively. Red blood cells were generally affected at doses slightly lower than those causing a decrease of white blood cell formation. Bone marrow changes reflected the effects on peripheral blood in rats and dogs. Atrophy of lymphoid organs, lymphocytolysis and/or lymphoid depletion were observed at oral doses &ge; 200 mg/kg in the rat and &ge; 30 mg/kg in the dog. A slight to moderate reduction in spermatogenesis was observed in the dog &ge; 30 mg/kg and in the rat fertility study at a dose of 60 mg/kg.</p><p>Enlarged corpora lutea with hemorrhagic fluid were observed in rats at doses &ge; 60 mg/kg and in dogs at 100&rarr;50 mg/kg/day. Diarrhea was observed in the dog at oral doses &ge; 3mg/kg/day. Emesis was observed at oral doses of &ge; 30 mg/kg in the dog and &ge; 75 mg/kg in the monkey. Atrophy of the intestinal mucosa, vacuolar degeneration of the gastrointestinal epithelium and single cell necrosis were observed at doses &ge; 10 mg/kg in the dog and at 600 mg/kg in the rat. The effects on bone marrow, lymphoid tissues, testis/ovaries, and gastrointestinal (GI) tract can be explained by an exaggerated pharmacological effect of imatinib on its different molecular targets.</p><p>The kidney was a target organ in rats and monkeys. In rats, hyperplasia of the transitional epithelium in the renal papilla and in the urinary bladder was observed at doses &ge; 6 mg/kg without changes in serum or urinary parameters. These findings may reflect local irritation of the compound to the urinary tract, since it has shown to be a local moderate irritant after i.v. administration. In monkeys, focal mineralisation and dilatation of renal tubules, and tubular nephrosis was seen in a 2-week oral dose range finding study at 150&rarr;100 mg/kg.</p><p>Biochemical changes indicating renal dysfunction (increased BUN and creatinine, electrolyte changes) were noted.</p><p>The liver was a target organ in rats and dogs. Increases in transaminases, and decreases in cholesterol, triglycerides, total protein and albumin were observed in both species. Liver toxicity was greater in dogs, as reflected by more extensive microscopic findings consisting of mild multifocal hepatocellular necrosis (single cell type) and single cell necrosis in bile ducts with reactive hyperplasia, and/or inflammation adjacent to blood vessels and bile ducts at doses &ge; 10 mg/kg, most pronounced at the100/50 mg/kg/day. After the recovery period, liver lesions were more severe than in the main study, associated with peribiliary fibrosis and increased incidence and severity of bile duct hyperplasia. Antinucleolar antibodies located in hepatocytes and in epithelial bile duct cells were detected in the 4-week dog exploratory study.</p><p>&nbsp;</p><p><strong>Reproductive Toxicity Studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Study Type</p></td><td><p>Species</p></td><td><p>Route</p></td><td><p>Doses (mg/kg)</p></td><td><p>Findings</p></td></tr><tr><td><p>Segment I</p></td><td><p>Rat</p></td><td><p>Oral</p></td><td><p>6, 20, 60</p></td><td><p>At 60 mg/kg, decreased testes and epididymal weights, decrease in percent motile sperm, increased post- implantation loss. NOEL for male and female fertility and early embryonic development = 20 mg/kg.</p></td></tr><tr><td><p>Segment II range-finding</p></td><td><p>Rat</p></td><td><p>Oral</p></td><td><p>30, 100, 300</p></td><td><p>At 300 mg/kg death &amp; total resorption. At 100 mg/kg increased post-implantation loss, decreased fetal weight &amp; teratogenicity. No changes at 30 mg/kg.</p></td></tr><tr><td><p>Segment II</p></td><td><p>Rat</p></td><td><p>Oral</p></td><td><p>10, 30, 100</p></td><td><p>At 100 mg/kg, post-implantation loss and teratogenicity. At 30 mg/kg protruded tongue and shortened 13th rib. NOEL = 10 mg/kg.</p></td></tr><tr><td><p>Segment II range-finding</p></td><td><p>Rabbit</p></td><td><p>Oral</p></td><td><p>10, 30, 100</p></td><td><p>At 100 mg/kg, embryo-fetaltoxicity; no reproductive changes at 10 or 30 mg/kg.</p></td></tr><tr><td><p>Segment II</p></td><td><p>Rabbit</p></td><td><p>Oral</p></td><td><p>6, 20, 60</p></td><td><p>At 60 mg/kg, slight delay in fetal development (ossification) and slight maternaltoxicity. No teratogenicity.</p></td></tr></tbody></table><p>&nbsp;</p><p>Reproductive toxicity studies indicated that imatinib has a teratogenic potential in rats at doses &ge; 30 mg/kg. A dose of 10 mg/kg appeared to represent the no effect level (NOEL). In rats, doses &ge;30 mg/kg induced embryo- fetal toxicity and/or teratogenicity (exencephaly, encephalocele, absent or reduced frontal, parietal and/or interparietal bones; dose-dependent protruded tongues) in surviving fetuses. In rabbits, there was no evidence &nbsp;of teratogenicity. Although testes and epididymal weights and percent motile sperm were decreased in male rats at 60 mg/kg, there were no effects on mating or on the number of pregnant females.</p><p>&nbsp;</p><p>Three groups of time-pregnant female rats (n=24/group) were administered STI571 orally by gavage at dosages of 5, 15 and 45 mg/kg/day. The animals were treated from gestation day 6 through lactation day 20.</p><p>&nbsp;</p><p>There was no maternal mortality. A red vaginal discharge was noted in the 45 mg/kg/day group on either day 14 or 15 of gestation. At this dose the number of stillborn pups was slightly increased while the number of viable pups and the number of pups dying between postpartum days 0 and 4 were decreased. In the F1 offspring, at the same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased. F1 fertility was not affected while an &nbsp;&nbsp;increased number of resorptions and a decreased number of viable fetuses was noted at 45 mg/kg/day. The No Effect Level (NOEL) for both the maternal animals and the F1 generation was 15 mg/kg/day (one-fourth the maximum human dose of 800 mg/day).</p><p>&nbsp;</p><p>Fertility was not affected in the preclinical fertility and early embryonic development study although lower testes and epididymal weights as well as a reduced number of motile sperm were observed in the high dose males rats. In the preclinical pre- and postnatal study in rats, fertility in the first generation offspring was also not affected &nbsp;&nbsp;by imatinib mesylate.</p><p>&nbsp;</p><p>Human studies on male patients receiving imatinib mesylate and its effect on male fertility and spermatogenesis have not been performed. Male patients concerned about their fertility on imatinib mesylate treatment should consult with their physician.</p><p>&nbsp;</p><p><strong>Juvenile Developmental Toxicology</strong></p><p>No new target organs were identified in the rat juvenile development toxicology study (day 10 to 70 post- partum). In the juvenile toxicology study, transitory effects upon growth and delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2 times the average pediatric exposure at the highest recommended dose of 340 mg/m2. Also, mortality was observed in juvenile animals (around weaning phase) at approximately 2-times the average pediatric exposure at the highest recommended dose of 340 mg/m2.</p><p>&nbsp;</p><p><strong>Carcinogenesis and Mutagenesis</strong></p><p>The genotoxic potential of imatinib was assessed in a battery of mutagenicity tests:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Study Type</p></td><td><p>Findings</p></td></tr><tr><td><p><em>In vitro</em>: Ames Salmonella and Escherichia/mammalian-microsome mutagenicitytest 30.9 &ndash; 5000 &mu;g/plate &plusmn; S9 (range)</p></td><td><p>Negative</p></td></tr><tr><td><p><em>In vitro </em>: Gene mutation test with Chinese hamster cells V79 range:</p><p>7.41 - 200 &mu;g/ml + S9</p><p>0.74 - 20 &mu;g/ml &ndash; S9</p></td><td><p>&nbsp;</p><p>Negative</p><p>Negative</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:748px"><tbody><tr><td style="width:676px"><p><em>In vitro</em>: Cytogenetic test on Chinese hamster cells CHO range: 31 - 125 &mu;g/ml + S9</p><p>1.5 - 12.5 &mu;g/ml &ndash; S9</p></td><td style="width:70px"><p>&nbsp;</p><p>Positive</p><p>Negative</p></td></tr><tr><td style="width:676px"><p><em>In vitro</em>: Mouse lymphoma mutagenicity assay range:</p><p>0.98 - 62.5 &mu;g/ml + S9</p><p>1.56 - 50 &mu;g/ml &ndash; S9</p></td><td style="width:70px"><p>&nbsp;</p><p>Negative Negative</p></td></tr><tr><td style="width:676px"><p><em>In vivo</em>: Rat micronucleus</p><p>Doses 25, 50 &amp; 100 mg/kg</p></td><td style="width:70px"><p>&nbsp;</p><p>Negative</p></td></tr></tbody></table><p>&nbsp;</p><p>Imatinib was devoid of genotoxicity in bacterial and cellular assays for mutagenic effects. The rat micronucleus assay which detects clastogenic and aneugenic effects was also negative. Positive results were obtained in an in vitro assay for clastogenicity (chromosome aberration) in the presence of metabolic activation, but only at concentrations which resulted in significant cytotoxicity.</p><p>In a 2-year rat carcinogenicity study, imatinib was administered in feed at doses of 15, 30 and 60 mg/kg/day, and resulted in a statistically significant reduction in the longevity of males rats at 60 mg/kg/day and females rats at</p><p>&ge;30 mg/kg/day. Histopathological examination of decedents revealed cardiomyopathy (both rats sexes), chronic progressive nephropathy (females rats) and preputial gland papilloma as principal causes of death or reasons for sacrifice. Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non-glandular stomach. The no observed effect levels (NOEL) for the various target organs with neoplastic lesions were established as follows: 30 mg/kg/day for the kidneys, urinary bladder, urethra, small intestine, parathyroid glands, adrenal glands and non-glandular stomach, and 15 mg/kg/day for the preputial and clitoral gland.</p><p>The papilloma/carcinoma of the preputial/clitoral gland were noted at 30 and 60 mg/kg/day in rats, representing (approximately 0.5 to 4 times the human daily exposure at 400 mg/day (based on AUC), 0.3 to 2.4 times the human daily exposure at 800 mg/day (based on AUC), and 0.4 to 3.0 times the daily exposure in children at 340 mg/m2 (based on AUC). The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumors of &nbsp;the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted only at 60 mg/kg/day.</p><p>Non-neoplastic histological lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td><p>colloidal silicon dioxide</p></td></tr><tr><td><p>crospovidone</p></td></tr><tr><td><p>magnesium stearate</p></td></tr><tr><td><p>hydroxypropyl cellulose</p></td></tr><tr><td><p>hypromellose</p></td></tr><tr><td><p>polyethylene glycol</p></td></tr><tr><td><p>red ferric oxide</p></td></tr><tr><td><p>yellow ferric oxide</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Strength</strong></p></td><td><p><strong>Pack Size(s)</strong></p></td><td><p><strong>Description of Container Closure</strong></p></td></tr><tr><td><p>100 mg</p></td><td rowspan="2"><p>Blister of 30&rsquo;s</p></td><td rowspan="2"><p>Film: Cold Formable Foil 205MM Foil: White Coated Foil 205MM 25UM</p></td></tr><tr><td><p>400 mg</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., 150 Signet Drive Toronto, Ontario, M9L 1T9 Canada.
Telephone: 416-401-7500
Fax: 416-401-3875
E-mail: support@apotex.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>